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Supervisor: Shinobu Watanabe-Galloway, Ph.D. 
Metabolic syndrome (MetS) is a cluster of metabolic disorders, including increased fasting 
glucose, blood pressure, plasma triglyceride, reduced high-density lipoprotein cholesterol 
and abdominal obesity. It leads to an increased risk of cardiovascular disease and diabe-
tes. The growing prevalence of MetS is strongly related to the increasing prevalence of 
overweight/obesity. As an antioxidant, lycopene can reduce the risk of MetS. However, it 
is unclear whether lycopene has similar effects among overweight/obese individuals and 
whether lycopene can reduce the risk of mortality among individuals with MetS. The pur-
pose of this study was to explore the roles of lycopene in the prevalence and mortality of 
MetS. Specifically, the main objective was to examine the associations between serum 
lycopene or the ratio of serum lycopene to serum triglyceride and MetS, and the associa-
tion between the ratio and mortality among individuals with MetS. In addition, the possible 
additive effects of physical activity and lycopene on MetS and mortality were studied. To 
achieve these objectives, analyses were conducted with participants aged 20 years and 
older from the NHANES 2001-2006. The tertile rank method was used to divide partici-
pants into three groups according to serum lycopene or the ratio. Logistic regression and 
Cox models were used for association analyses. With serum lycopene, the associations 
between lycopene and MetS were only significant for normal weight/overweight (p<0.05), 
but not for obese participants (p>0.05). While with the ratio, the associations between 
lycopene and MetS were significant not only for normal weight/overweight (p<0.05), but 




and second tertile groups had significantly reduced hazard ratios of mortality for partici-
pants with MetS. The additive effect of lycopene and physical activity was significant for 
overweight (p<0.05) but not for obese participants (p>0.05). There was no an additive 
effect of lycopene and physical activity on mortality among participants with MetS. There-
fore, the study adds new evidence that the ratio of serum lycopene to serum triglyceride 
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CHAPTER 1 INTRODUCTION 
1.1. Metabolic Syndrome 
Metabolic syndrome is a cluster of metabolic disorders, including increased fasting 
glucose, blood pressures, plasma triglyceride, and reduced high-density lipoprotein (HDL) 
cholesterol concentrations and abdominal obesity [1]. According to the National Choles-
terol Education Program’s Adult Treatment Panel III, to be diagnosed with metabolic 
syndrome, an individual has to meet three or more of the following criteria: abdominal 
obesity (waist circumference>40 inches for men and>35 inches for women); hypertriglyc-
eridemia (serum triglyceride≥1.69 mmol/L); low HDL-cholesterol (HDL<1.04 mmol/L for 
men and<1.29 for women); hypertension (≥130/85 mmHg) and high fasting glucose (fast-
ing glucose≥6.1 mmol/L) [2]. With the diagnosis criteria, approximately 27% of adults, 
aged 20 years and older, had metabolic syndrome in 2000 based on the National Health 
and Nutrition Examination Survey (NHANES) 1999–2000 [2]. Metabolic syndrome is com-
mon among overweight and obese individuals, and leads to an increased risk of 
cardiovascular disease and type 2 diabetes mellitus [1, 2]. Additionally, metabolic syn-
drome is associated with increased risks for certain cancers, including breast [3], 
endometrial [4], colorectal [5] and biliary tract cancers [6], and an increased risk for all-
cause mortality [7, 8]. Thus, given the number of affected individuals and the associated 
disease risks, metabolic syndrome is an important public health concern in the United 
States.  
Although the mechanisms behind metabolic syndrome are not entirely clear, accumu-
lating evidence supports that chronic inflammation and oxidative stress play important 
roles in its development [9, 10]. For example, increased body mass index (BMI) is found 




metabolic syndrome strongly correlates with an increased prevalence of overweight and 
obesity [11-13].  
1.2. Health Effects of Lycopene 
There have been a number of different strategies or interventions intended to mitigate 
the oxidative stress and/or inflammation. One is the therapeutic drug strategy. For exam-
ple, salsalate, a traditional anti-inflammatory medication, can prevent the metabolic 
syndrome in obese non-diabetic individuals [14]. Probucol, a potent anti-oxidant drug, has 
been in clinical use during the past few decades for prevention of cardiovascular diseases 
[15]. While these therapeutic drug strategies that target weight-related oxidative stress 
and/or inflammation can potentially reduce chronic disease burdens, often these anti-oxi-
dants and anti-inflammatory drugs have serious side effects in long-term disease 
prevention. For example, approximately 30% of patients discontinued use of salsalate be-
cause of gastrointestinal symptoms and tinnitus [16] and many patients discontinued use 
of probucol because of the space between the start of the Q wave and the end of the T 
wave (Q-T interval) prolongation [17].  
A diet rich in antioxidants is another potential approach to reduce oxidation and inflam-
mation. Therefore, nutrient intake from food, such as lycopene, may be an ideal option for 
long-term disease prevention. As a nutrient, lycopene is mainly contained in tomatoes and 
other vegetables or fruits, such as red carrots and watermelons. The biological mecha-
nisms of lycopene on metabolic syndrome and chronic diseases include alleviating 
oxidative stress and inhibiting inflammation in the body [18-22]. Studies found there is a 
significant association between metabolic syndrome and lycopene [23-25]. For example, 
Sluijs et al, found that higher lycopene intake is associated with a lower prevalence of 
metabolic syndrome in middle-aged and elderly men [23]. Liu et al. found that higher se-




middle-aged and elderly Chinese adults [24]. Yeo et al. also found there is a significantly 
positive association between metabolic syndrome and serum lycopene among Korean 
men [25]. Further, epidemiologic studies have shown that lycopene can significantly re-
duce the risks of chronic diseases. For example, since the first report that lycopene can 
reduce the incidence rate of prostate cancer in 1995 [26], lycopene has been found to be 
inversely associated with breast, cervical, ovarian, liver and other organ sites cancers [27]. 
In addition to tumor-suppressing activity, lycopene is found to decrease the risks of devel-
oping other chronic diseases, such as cardiovascular disease [28-30] and cerebrovascular 
disease [31].  
Despite accumulating evidence to support health effects of lycopene, it is not clear 
whether lycopene has similar effects among individuals who are overweight or obese. 
Many recent studies on lycopene have focused on people who are overweight or obese 
[32-37]; however, the results remain inconclusive. For example, some studies found that 
lycopene intervention can significantly reduce inflammation and oxidative stress in partic-
ipants who are overweight and obese [32-35], while other studies did not find significant 
associations between lycopene and inflammation and oxidative stress in overweight or 
obese individuals [36, 37].  
One of the potential reasons for varying effects of lycopene is differences in the 
amount of serum lycopene in these studies. Two cell culture studies found a dose-de-
pendent relationship between the serum lycopene concentration and the amount of 
reduction in inflammation and oxidative stress [38, 39]. These findings explain non-signif-
icant results of lycopene studies when the serum concentration was notably lower. 
Another point to consider when interpreting the research findings on lycopene is variations 
in the level of oxidation and inflammation in different individuals. By definition, compared 




of oxidation and inflammation. It is possible that among overweight and obese individuals 
with already high oxidation and inflammation levels, a substantially larger amount of lyco-
pene needs to be applied in order to have observable changes. This may indicate that the 
lycopene effect on oxidation and inflammation is not linear; there may be some thresholds 
in the BMI levels (as indicators of existing inflammation and oxidation levels) at which 
points, considerably more lycopene needs to be added as nutrients before its positive 
effects can be observed.   
A triglyceride is an ester consisting of one glycerol molecule bonded with three fatty 
acid molecules. As a serum lipid, it helps enable the bidirectional transference of adipose 
fat and blood glucose from the liver. There is a strong association between serum triglyc-
eride and BMI statuses [40]. Furthermore, serum concentration of triglyceride is 
significantly associated with increased oxidative stress [41] and increased levels of inflam-
mation [42]. Therefore, serum triglyceride can be regarded as an indicator of existing 
inflammation and oxidation levels in the body.  
Taken together, health effects of serum lycopene may depend not only on serum con-
centrations, but also on the amount of inflammation and/or oxidative stress in the body. 
Therefore, the ratio of the serum concentration of lycopene to the amount of inflammation 
and/or oxidative stress can better predict the association between lycopene and positive 
health effects than with only the serum concentration of lycopene. There is no method to 
directly measure the amount of inflammation and/or oxidative stress in the body. Given 
that serum triglyceride is an indicator of existing inflammation and oxidation levels in the 





1.3. Roles of Physical Activity  
Physical activity has been shown to prevent metabolic syndrome for individuals who 
are overweight and obese [43-45]. The biological mechanisms by which physical activity 
prevents metabolic syndrome include reducing abdominal adipose tissue, serum concen-
tration of triglyceride, and blood pressure, and increasing high-density lipoprotein and 
insulin sensitivity [46]. In addition, physical activity can prevent metabolic syndrome by 
decreasing inflammation and inducing an anti-inflammatory environment [47, 48]. For ex-
ample, physical activity can simultaneously decrease inflammatory cytokines, such as 
TNF-α and interleukin-6, and increase anti-inflammatory cytokines, such as interleukin-10 
[49-51]. 
There is a similarity in the way lycopene and physical activity both impact metabolic 
syndrome. For example, both decrease inflammatory cytokines like TNF-α and interleukin-
6 [20, 21 and 52] and increase anti-inflammatory cytokines like interleukin-10 [53, 54]. Due 
to common biological mechanisms by which physical activity and serum lycopene reduce 
the risk of metabolic syndrome by regulating inflammatory cytokines, it is natural to posit 
that there will be an additive effect between physical activity and serum lycopene on met-
abolic syndrome. Although both physical activity and lycopene can reduce the risk of 
morbidity and mortality of metabolic syndrome, studies suggest that the effects of physical 
activity or lycopene alone are insufficient to substantially reduce the risk of metabolic syn-
drome for overweight and obese individuals [44]. Examining the additive effect between 
physical activity and serum lycopene is important for further reducing the risk of metabolic 




1.4. Potential Effects of Lycopene on Mortality 
As mentioned above, metabolic syndrome has an increased risk of all-cause mortality 
as well as cardiovascular related mortality [7, 8]. Although the reasons for the higher mor-
tality are not entirely clear, accumulating epidemiologic evidence supports that higher 
mortality may be largely attributable to increased risks of cardiovascular disease, diabetes 
and stroke-related morbidity and mortality in individuals with metabolic syndrome [8, 55 
and 56]. There are more inflammation and oxidative stress in individuals with metabolic 
syndrome than individuals without metabolic syndrome [57]. Increased inflammation and 
oxidative stress lead to the increased risk of cardiovascular disease, diabetes and stroke 
[58-60].  
Past epidemiologic studies suggest that lycopene can reduce the risk of cardiovascu-
lar diseases [28-30] and stroke [31]. In addition, lycopene was found to reduce the 
mortality in the general population [61, 62], in patients with Alzheimer’s disease, and in 
patients with obstructive lung function [63, 64]. However, some intervention studies did 
not find significant associations between lycopene and cardiovascular diseases [65, 66] 
and mortality [67]. Therefore, results on the beneficial role of lycopene as an antioxidant 
in the prevention of cardiovascular diseases and mortality remain conflicted [68]. Although 
all studies claimed that serum concentration of lycopene increased, high increase of se-
rum lycopene at the baseline (0.371umol/L for women and 0.258 umol/L for men) had a 
significant positive effect on mortality [61] while a small increase of serum lycopene at the 
baseline (0.16 μmol/L) had no significant positive effect on mortality [67]. Therefore, dif-
ferent criteria for change in serum concentration of lycopene may be an alternative 
explanation for these inconsistent results. For this reason, the ratio of the serum concen-




concentration of lycopene) was used to predict the association between lycopene and 
mortality.  
1.5. Effects of Physical Activity on Mortality 
A study found that physical activity is significantly associated with reduced mortality in 
patients with metabolic syndrome [69]. In this prospective study of more than 13,000 men 
and women with metabolic syndrome, after 10 years following-up, the authors found that 
individuals with metabolic syndrome who reported high levels of physical activity at base-
line were at a reduced risk of death from all causes compared to those who reported no 
physical activity [69]. However, metabolic syndrome has a high risk of all-cause mortality 
as well as cardiovascular related mortality [7, 8]. Therefore, to maximize the reduction of 
deaths among individuals with metabolic syndrome, it is necessary to explore whether a 
combination of physical activity and lycopene has a stronger effect on mortality than phys-
ical activity or lycopene alone.   
1.6. Summary of Research Gaps 
Gap 1: Lycopene can reduce the risk of metabolic syndrome by alleviating oxidative 
stress and inhibiting inflammation; the health effects of lycopene on inflammation and ox-
idative stress are not significant for obese individuals; the question is whether the health 
effect of lycopene on metabolic syndrome is significant among obese individuals.  
Gap 2: Due to the fact that the effects of lycopene depends on the serum concentration 
of lycopene and the amount of inflammation and oxidative stress, the question is whether 
the ratio of serum lycopene to the amount of inflammation and oxidative stress can better 




Gap 3: Metabolic syndrome has an increased risk of mortality, lycopene can reduce 
the risk of mortality in general population and some patients, and the question is whether 
lycopene can reduce the risk of mortality among individuals with metabolic syndrome. 
Gap 4: Although both physical activity and lycopene can reduce the risk of metabolic 
syndrome, both alone are insufficient for the risk. The question is whether physical activity 
and lycopene have an additive health effect on metabolic syndrome. 
Gap 5: Although both physical activity and lycopene can reduce the risk of mortality of 
metabolic syndrome, both alone are insufficient for the risk. The question is whether phys-
ical activity and lycopene have an additive health effect on mortality. 
1.7. Study Purpose and Specific Aims 
The purpose of this study was to explore the roles of lycopene on the morbidity and 
mortality of metabolic syndrome by using a large population-based database. There were 
five specific aims. 
Specific Aim 1: To examine the association between serum concentration of lycopene 
and the prevalence of metabolic syndrome for individuals with different BMI levels. Hy-
pothesis: The association between serum lycopene and metabolic syndrome is influenced 
by different BMI levels. 
Specific Aim 2: To examine the association between the ratio of serum lycopene to 
serum triglyceride and the prevalence of metabolic syndrome for individuals with different 
BMI levels. The association between the ratio of serum lycopene to serum triglyceride and 
metabolic syndrome is influenced by different BMI levels. 
Specific Aim 3: To examine the effect of lycopene on mortality in individuals with met-
abolic syndrome. Hypothesis: Serum lycopene can reduce the risk of mortality for 




Specific Aim 4: To examine the possible additive effect of physical activity and serum 
lycopene on the prevalence of metabolic syndrome among overweight and obese individ-
uals.  
Specific Aim 5: To examine the possible additive effect of physical activity and serum 
lycopene on mortality among individuals with metabolic syndrome.  
1.8. Theoretical Framework 
An increased risk of metabolic syndrome occurs in overweight/obese individuals due 
to increased chronic inflammation and oxidative stress [11-13]. Lycopene, as a natural 
antioxidant, can alleviate oxidative stress and inhibit inflammation [18-22]. Therefore, in-
creased serum lycopene has the potential to decrease the risk of metabolic syndrome in 
individuals who are overweight and obese.  
However, the health effects of lycopene on reducing inflammation and oxidative stress 
in individuals who are overweight and obese remain inconclusive [32-37]. Health effects 
of serum lycopene may depend not only on serum concentrations, but also on the amount 
of inflammation and/or oxidative stress in the body. Therefore, the ratio of the serum con-
centration of lycopene to the amount of inflammation and/or oxidative stress can better 
predict the association between lycopene and positive health effects than serum concen-
tration of lycopene alone can. There is no method to directly measure the amount of 
inflammation and/or oxidative stress in the body. Given the strong associations between 
oxidative stress and inflammation, this study used serum triglyceride to represent the 
amount of inflammation and/or oxidative stress. Therefore, in this study, we examined the 





Metabolic syndrome also increases the risk of death from all causes as well as cardi-
ovascular diseases [7, 8]. In addition to decreasing the risk of cardiovascular diseases, 
lycopene was also found to reduce the mortality in the general population [61, 62] and in 
patients with Alzheimer’s disease or obstructive lung function [63, 64]. Therefore, serum 
lycopene also has a potential to reduce the risk of mortality for individuals with metabolic 
syndrome. However, some intervention studies did not find significant associations be-
tween lycopene and cardiovascular diseases [65, 66] and mortality [67]. Different criteria 
for the amount of increase in the serum concentration of lycopene may be an alternative 
explanation for these inconsistent results. For this reason, the ratio of the serum concen-
tration of lycopene to the amount of inflammation and/or oxidative stress (relative serum 
concentration of lycopene) was used to predict the association between lycopene and 
mortality in this study. 
As a healthy lifestyle, physical activity can reduce the risk of metabolic syndrome [43-
45] and mortality [69]. Due to common biological mechanisms by which physical activity 
and serum lycopene regulate inflammatory cytokines [20, 21, 49-54], it is natural to posit 
that there will be additive effects between physical activity and serum lycopene on meta-
bolic syndrome and mortality. Therefore, we examined the possible additive effects of 
physical activity and lycopene on metabolic syndrome and mortality in this study.  
Figure 1 shows a conceptual model developed for this study. Overweight and obese 
individuals have a higher risk to develop metabolic syndrome than normal weight individ-
uals. Individuals with metabolic syndrome have a higher risk of mortality than individuals 
without metabolic syndrome. An increased risk of metabolic syndrome occurs in over-
weight/obese individuals due to increased chronic inflammation and oxidative stress. 
Lycopene, as a natural antioxidant, can alleviate oxidative stress and inhibit inflammation. 




syndrome among overweight and obese individuals. Metabolic syndrome also increases 
the risk of death from all causes as well as cardiovascular diseases. In addition to de-
creasing the risk of cardiovascular diseases, lycopene was also found to reduce the 
mortality in the general population and patients with Alzheimer’s disease or obstructive 
lung function. Therefore, we also hypothesized that lycopene has the potential to reduce 
the risk of mortality for individuals with metabolic syndrome. In addition, due to common 
biological mechanisms by which physical activity and serum lycopene regulate inflamma-
tory cytokines, we hypothesized that there were additive effects of physical activity and 
lycopene on metabolic syndrome and mortality. 
Figure 1. Conceptual model of metabolic syndrome 
 
1.9. Scope of the Study 
The study took advantage of the NHANES database, a unique population-based sur-
vey and laboratory measruments, which collects information about the health and nutrition 
intake of adults and children [70]. The NHANES sample represents the United States non-




The data collection in NHANES included a home interview and a follow-up physical ex-
amination. The CDC institutional review board approved the survey; in addition, before 
participants took part in the study, they all signed written informed consent forms. In this 
study, only adult participants who were at least 20 years of age were included. The com-
bination of NHANES 2001–2006 included 15,431 adult participants (7,341 men and 8,090 
women).  
1.10. Summary 
In this chapter, we first described the background of the research problems. Metabolic 
syndrome is an important health condition because it is directly related to a high risk of 
chronic diseases and mortality. The growing prevalence of metabolic syndrome is related 
to the increasing prevalence of overweight and obesity. Therefore, exploring healthy life-
styles, such as diet and physical activity, is very important to reduce the prevalence and 
mortality of metabolic syndrome for overweight and obese individuals. We stated our re-
search purposes, specific aims/research hypotheses and theoretical framework. Lastly, 
we described the population source for this study. The data in this study was obtained 
from the NHANES from 2001 to 2006. The study is important because the findings can 
provide an important analysis method (the ratio of serum lycopene to serum triglyceride) 




CHAPTER 2 REVIEW OF THE LITERATURE 
2.1. Overweight and Obesity 
Overweight and obesity are referred to be a body weight that’s greater than what is 
considered healthy for a certain height [71]. BMI, an expression with weight divided by 
height squared (kg/m2), is a common measure for classification of overweight and obesity 
because it is inexpensive and easy to use for clinicians and for the general public. An adult 
with a BMI between 25.0 and 29.9 kg /m2 is considered to be overweight and an adult with 
a BMI of 30 kg/m2 or higher is considered to be obese. For children and adolescents, when 
a BMI number is plotted on a specific growth chart, we can find a relative position for this 
BMI (specific gender-age-percentile). If his/her BMI is located between 85th and 95th per-
centile, he/she is considered as overweight; if his/her BMI is located equal or greater than 
95th percentile, he/she is considered as obese [72].    
According to the Global Burden of Disease Study, approximately 35% adults aged 20 
years and above were overweight or obese in 2008 around the world [73]. Obesity epi-
demic has become a major public health problem in the United States. The prevalence of 
obese adults had more than doubled from 15% in 1976-1980 to 36% in 2009-2010 in the 
country [74]. The prevalence of adults who are overweight or obese was 68% for the pe-
riod 2011-2012 [75]. This means two-thirds of American adults are either overweight or 
obese. According to Allison et al., 280,000 to 325,000 deaths per year are attributable to 
overweight and obesity and their complications in the United States. [76].  
Overweight and obesity place a dramatic burden on families and society. There are 
many methods for economic estimation; the common methods include the direct and indi-
rect cost estimations [77]. Direct costs include physician visit and hospital or nursing home 




In 1995, the total estimated costs related to overweight and obesity were approximately 
$99.2 billion, including $51.6 billion in direct costs and $47.6 billion in indirect costs [77]. 
By 2000, the total costs of overweight and obesity were $117 billion, with $61 billion in 
direct costs and $56 billion in indirect costs [78]. For youths aged 6 to 17 years, overweight 
and obesity-related hospital costs had increased three times from $35 million (1979-1981) 
to $127 million (1997-1999) per year [79]. Overweight and obesity had led to over 1.3 
billion long-term care patient days and over $68 billion Medicaid costs (in 2012 value) 
among baby boomers [80].  
2.2. Roles of Excess Weight and Metabolic Syndrome in Development of Chronic 
Diseases 
These significant public health burdens related to overweight and obesity mainly con-
tribute to its high risk of developing chronic diseases, such as cardiovascular disease [81, 
82], cerebrovascular disease [83] diabetes [84], osteoarthritis [85], non-alcoholic fatty liver 
disease [86] and cancers [87]. Cardiovascular disease, cerebrovascular disease and dia-
betes are some of the leading causes of mortality in the world [88]. Accumulating 
epidemiological evidence supports that a cluster of metabolic disorders in overweight and 
obese individuals is related to high risks of developing cardiovascular and cerebrovascular 
diseases. The cluster of metabolic disorders includes insulin resistance or higher fasting 
glucose, higher blood pressures, higher plasma triglyceride, and lower HDL cholesterol 
concentrations. For example, the growing prevalence of insulin resistance is significantly 
related to increasing BMI [89]. The prevalence of hypertension is higher in obese (35.7%) 
and overweight (26.4%) than in normal weight adults (19.8%). And the prevalence of 
dyslipidemia is higher in obese (49.7%) and overweight (44.2%) than in normal weight 




syndrome (syndrome X) at first [91, 92], then was named as metabolic syndrome lately 
[93]. 
2.3. Metabolic Syndrome 
According to the American Heart Association and the National Heart, Lung, and Blood 
Institute, metabolic syndrome is defined as a condition in which a group of metabolic risk 
factors exist in an individual. These risk factors, such as obesity, dyslipidemia, elevated 
blood pressure, insulin resistance, are directly related to a high risk of cardiovascular dis-
ease and type 2 diabetes mellitus [1]. 
Currently, there are at least three clinical diagnosis criteria recommended for meta-
bolic syndrome. According to the World Health Organization (WHO), if an individual has 
glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus (DM) and /or 
insulin resistance together with two or more of the following components: raised arterial 
pressure (greater and equal to 140/90 mmHg); dyslipidemia [elevated plasma triglycerides 
(greater and equal to 1.7mmol/L) and/or decreased HDL-cholesterol (less than 0.9 mmol/L 
for men and less than 1.0 mmol/L for women)]; central obesity (waist to hip ratio great than 
0.90 for men and great than 0.85 for women) and/or BMI greater than 30 kg/m2; and mi-
croalbuminuria (urinary albumin excretion rate greater and equal to 20 ug/min or albumin 
to creatinine ratio greater and equal to 30 mg/g) [94]. The American Association of Clinical 
Endocrinologists proposes another set of clinical criteria: overweight/obesity (BMI greater 
and equal to 25 kg/m2); elevated triglycerides (greater and equal to 1.69 mmol/L); low 
HDL-cholesterol (less than 1.04 mmol/L for men and less than 1.29 mmol/L for women); 
elevated blood pressure (greater and equal 130/85 mmHg); two hours post-glucose chal-
lenge (greater than 140 mg/dl); fasting glucose (between 110 mg/dl and 126 mg/dl) and 
other risk factors (such as family history of T2DM, hypertension, or CVD; sedentary life-




Cholesterol Education Program’s Adult Treatment Panel III report (ATP III), if an individual 
has three or more of the following criteria, he/she will be diagnosed with metabolic syn-
drome: abdominal obesity (waist circumference greater than 102 cm for men and greater 
than 88 cm for women); hypertriglyceridemia (greater and equal to 1.69 mmol/L); low HDL-
cholesterol (less than 1.04 mmol/L for men and less than 1.29 mmol/L for women); hyper-
tension (greater and equal to 130/85 mmHg) and high fasting glucose (greater and equal 
to 6.1 mmol/L) [96].  
Using the ATP III criteria, Ford et al. found the prevalence of metabolic syndrome 
among the United States adults was 24.0%. The study was based on the third National 
Health and Nutrition Examination Survey (NHANES III) from 1988 to 1994 [97].  
Due to increased prevalence of overweight and obesity in the United States, the prev-
alence of metabolic syndrome continues to increase. Using the ATP III criteria, Aguilar et 
al. found the prevalence of metabolic syndrome among United States adults to be 32.9% 
during 2003-2004 and 34.7% during 2011-2012 based on NHANES 2003-2012 [98]. 
2.4. Inflammation, Oxidative Stress, Obesity and Metabolic Syndrome 
Why is the percent of metabolic syndrome higher in individuals who are overweight 
and obese than individuals who have normal weight? Inflammation and oxidative stress 
are the central mechanisms connecting overweight and obesity to metabolic syndrome 
[11, 12, 99, 100]. Studies show that adipose tissue is one of the sources of inflammation 
and oxidative stress [101-105]. For example, many inflammatory cytokines, such as TNF-
α, IL-1β, IL-6, IL-8, IL-10 and leptin can produce in adipose tissue [101-103]. In addition 
to cytokines, adipose tissue can produce lipid peroxides and oxidative stress, such as 
reactive oxidative metabolites [104, 105].  Therefore, excess adipose tissue can lead to 




example, there are significantly increased oxidative stress (oxidized low-density lipopro-
tein and reactive oxygen species) and low-grade inflammation (C-reactive protein and 
leptin) in obese individuals when compared to normal weight individuals [13, 106]. In ad-
dition, antioxidant enzymes and total plasma antioxidant capacity are suppressed in 
overweight and obese condition. For example, dietary-induced obesity can decrease an-
tioxidant enzymes, such as superoxide dismutase (SOD), glutathione peroxidase in adult 
rats [107]. Furthermore, adipose glutathione peroxidase was greatly suppressed by proox-
idative conditions such as high levels of TNF-α and hypoxia [108].  
2.5. Prevention and Treatment of Metabolic Syndrome 
Prevention of metabolic syndrome is needed to address several risk factors and re-
duce inflammation and oxidative stress in the body while treatments of metabolic 
syndrome are needed to control the components of metabolic syndrome. 
 Although metabolic syndrome can be caused by genetic factors, aging, smoking, un-
healthy diets and inactive lifestyles [98, 109 and 110], overweight and obesity is the pri-
mary reason for metabolic syndrome [111]. Therefore, in addition to quitting smoking and 
keeping an active lifestyle, controlling weight is very important for the prevention of meta-
bolic syndrome. Preventing overweight and obesity is an important step to reduce the 
prevalence of metabolic syndrome and chronic disease conditions and reduce the finan-
cial burden on patients’ families and society. However, although some interventions 
related to overweight and obesity have been developed to improve the health of individu-
als and populations in recent years [112-114], the prevalence of overweight and obesity 




Overweight and obesity are associated with increased oxidative stress and chronic 
inflammation status that favors the development of metabolic syndrome. Therefore, alle-
viating oxidative stress and/or suppressing inflammation is an alternative strategy to 
reduce the prevalence of metabolic syndrome among individuals who are overweight and 
obese. One is the therapeutic drug strategy. For example, salsalate, a traditional anti-
inflammatory medication, can prevent metabolic syndrome in obese non-diabetic individ-
uals [14]. Probucol, a potent anti-oxidant drug, has been in clinical use during the past few 
decades for the prevention of cardiovascular diseases [15]. However, these therapeutic 
drug strategies that target weight-related oxidative stress and/or inflammation can poten-
tially reduce chronic disease burden, but often anti-oxidants and anti-inflammatory drugs 
have serious side effects in long-term disease prevention, such as approximately 30% of 
patients discontinued the use of salsalate because of gastrointestinal symptoms and tin-
nitus [16] and many patients discontinued the use of probucol because of QT interval 
prolongation [17]. 
A diet rich in antioxidants is another potential approach to reduce oxidation and inflam-
mation. Carotenoids are a group of antioxidants that are found in fruits and vegetables. 
There are over 600 different carotenoids identified, however, approximately 90% of carot-
enoids are represented by the common dietary carotenoids including α-carotene, β-
carotene, lycopene, lutein and β-cryptoxanthin [115]. Α-carotene, β-carotene, and β-cryp-
toxanthin can convert to retinal and have vitamin A activity while lycopene and lutein 
cannot convert to retinal and therefore have no vitamin A activity [116]. After absorption, 
carotenoids are mainly distributed in the adipose tissue [117, 118]. Β-carotene and lyco-
pene are the predominant components of carotenoids in the adipose tissue, approximately 
20% of total carotenoids respectively [118]. Due to its higher tissue concentration and 




studies [119-122]. However, β-carotene may play double roles since β-carotene can pro-
mote health when taken at a lower level while β-carotene can bring adverse effects when 
taken at a higher level [115,120 and 121]. In addition, lycopene is discovered to be the 
most potent antioxidant; therefore, lycopene has attracted the attention of scientists 
around the world [123, 124]. 
2.6. Lycopene 
As a natural antioxidant, lycopene can alleviate oxidative stress induced in animal 
models [125, 126]. Dietary intake of tomatoes or purified lycopene supplementation has 
also decreased the oxidative damages in humans [18, 19, 127 and 128]. For example, 
lycopene supplementation can reduce 86% of induced lipid peroxidation in monkey cells 
[125]. In humans, consumption of tomato products can reduce lipoprotein sensitivity to 
oxidative damage [18] and reduce biomarkers of oxidative stress, such as lipid peroxida-
tion and DNA damage [19, 127 and 128]. 
Lycopene is a red pigment found primarily in tomatoes. Structurally, lycopene, assem-
bled from eight isoprene units, is a tetraterpene that is not soluble in water. Like all other 
carotenoids, lycopene is a polyunsaturated hydrocarbon. Lycopene's antioxidant activity 
attributes to its eleven conjugated double bonds [129]. The main source of lycopene for 
humans is from dishes prepared with vegetables and fruits which contain lycopene. Lyco-
pene is mainly contained in tomatoes and other vegetables or fruits, such as red carrots 
and watermelons. There is about 3,014 µg lycopene per 100g tomatoes; 1µg per 100g 
carrots and 4,532 µg per 100g watermelon [130]. 
In general, there are two kinds of lycopene, trans-lycopene and cis-lycopene. Trans-
lycopene is its natural form that is long and straight while cis-lycopene is a bent form that 




and tomato products, while cis-lycopene makes up more than 50% of the total lycopene 
in human plasma [131, 132]. Isomerization is a process that converts trans-isomers to cis-
isomers. Although the majority of isomerization is reported to occur in vivo, the mechanism 
of converting trans-lycopene to cis-lycopene in serum and tissues is not clear [133]. Trans-
lycopene and cis-lycopene have similar chemical properties. There is no significant differ-
ence in antioxidant activity between trans-lycopene and cis-lycopene [134].  
  2.7. Mechanism of Lycopene 
After absorption from the intestine, lycopene is primarily distributed in adipose tissue 
(60-72%), liver (17-23%), and serum or plasma (5-6%) [135]. Although the mechanism of 
different distribution of lycopene is unclear, the distribution varying in different tissue may 
suggest different functions for different tissues [135]. Lycopene concentrations at different 
adipose tissue sites (abdomen, buttock, and thigh) have positive correlations with serum 
lycopene concentration [136]. As a natural antioxidant, lycopene can alleviate oxidative 
stress induced in animal models [125, 126]. Dietary intake of tomatoes or purified lycopene 
supplementation has also decreased the oxidative damages in humans [18, 19, 127 and 
128]. In addition, animal experiments demonstrate that lycopene can significantly de-
crease pro-inflammatory cytokine and chemokine expression by inhibiting the TNFα-
mediated activation of the NF-κB signaling pathway in vitro and in vivo [20, 21]. Therefore, 
alleviating oxidative stress and suppressing inflammation may be the main mechanisms 
for the effects of lycopene [137]. Serum concentrations of lycopene were measured using 
high-performance liquid chromatography with multi-wavelength photodiode-array absorb-
ance detection [138]. 
Lycopene was found to reduce the risks of developing chronic diseases. For example, 




1995 [26], lycopene has been found to be inversely associated with breast, cervical, ovar-
ian, liver and other organ site cancers [27]. In addition to tumor-suppressive activity, 
lycopene is found to reduce the risks of developing other chronic diseases, such as cardi-
ovascular diseases and cerebrovascular diseases. These studies can usually be divided 
into dietary intake lycopene studies and serum lycopene studies. In general, studies based 
on lycopene intake failed to detect a significant association between lycopene and cardi-
ovascular diseases and cerebrovascular diseases [139-141]. Misclassification of dietary 
lycopene intake may be an alternative explanation for the failure of these dietary studies 
[142].  
There were many studies which examined the associations between lycopene and 
heart diseases. Kohlmeier and colleagues found that there was a dose-response inverse 
association between lycopene and myocardial infraction with a population-based case-
control study in Europe (EURAMIC Study) [28]. Karppi and colleagues also found that low 
serum lycopene increased the risk of myocardial infarction in Finnish men [29]. However, 
Hak and colleagues did not find an association between serum lycopene and the risk of 
myocardial infarction in United States male physicians [65]. For coronary heart disease in 
Czech, Bavarian and Israeli men, Bobak and colleagues found there was a significant 
association between lycopene and coronary heart disease [30]. A cohort study (the Kuopio 
Ischaemic Heart Disease Risk Factor Study) found that the lower level of serum lycopene 
was associated with increased risks of coronary heart disease with 6 years of follow-up 
for Finnish people [31]. 
For stroke, Rissanen and colleagues found low serum levels of lycopene was associ-
ated with an increased risk of stroke with 6 years of follow-up for Finnish people [31]. With 
the same cohort data, Karppi and colleagues also found low serum levels of lycopene 




For the combination of disease conditions, Sesso and colleagues found that high levels of 
plasma lycopene concentration can reduce the incidence rate of cardiovascular disease 
in women [144]. However, Sesso and colleagues did not find that high plasma lycopene 
concentration was associated with the risk of cardiovascular disease in older men [66].  
In addition to reducing the risk of cardiovascular disease and cerebrovascular disease, 
lycopene was found to improve endothelial function in participants with cardiovascular 
disease [145]. Kristenson and colleagues found that the mortality from coronary heart dis-
ease in Lithuania was associated with serum concentration of lycopene [146]. Ito and 
colleagues also reported that lycopene played an important role in preventing death from 
cardiovascular diseases in Japanese patients [61]. However, Karppi and colleagues did 
not find an association between the risk of cardiovascular disease mortality and serum 
concentration of lycopene among Finnish men [67].  
For all-cause mortality, with NHANES III data, Patel and colleagues found that serum 
concentration of lycopene was negatively related to all-cause mortality [62]. However, with 
the same data, Shardell and colleagues only found the middle two quartiles had an asso-
ciation with all-cause mortality while the lowest quartile and the highest quartile had no 
association with all-cause mortality [147]. Furthermore, the authors found high serum con-
centration of lycopene up to 0.40 µmol/L was associated with a reduced mortality. Starting 
at 0.50 µmol/L, a high serum concentration of lycopene was associated with increased 
mortality (P<0.001). Therefore, the authors indicated that there may be a U-shaped rela-
tionship between serum lycopene and mortality [147]. 
2.8. Lycopene Measurement and Factors Associated with Lower Serum Lycopene  
Usually, there are two methods for lycopene measurement: serum concentration of 




tissue [135], it is not common to test lycopene concentration in adipose tissue because it 
is inconvenient to detect in these tissues. In addition, serum lycopene concentration has 
a positive correlation with lycopene concentration in adipose tissue [136]. Therefore, se-
rum or plasma lycopene is the common measure for humans. Lycopene concentration 
can be measured in serum by reverse-phase high-performance liquid chromatography [33] 
while dietary intake of lycopene can be estimated by using 24-hour food recalls (values 
were converted to mg per day based on checklist of tomato-based foods) [34]. Serum 
concentration of lycopene is an objective test measurement while dietary intake of lyco-
pene is an subjective measurement of self-reported data. Therefore, serum concentration 
of lycopene is more valid and reliable than dietary intake of lycopene [142].    
Studies show that there are several factors related to high (or low) levels of serum 
lycopene. For example, race/ethnicity, gender and age have associations with serum con-
centration of lycopene [148-150]. In addition, lifestyles can impact serum concentration of 
lycopene. For example, cigarette smoking was inversely associated with serum concen-
tration of lycopene [151]. The effects of alcohol consumption on serum concentration of 
lycopene are inconsistent in previous reports [152, 153]. 
2.9. Lycopene Levels among Overweight and Obese Individuals 
Individuals who are overweight or obese tend to have less healthy dietary habits. For 
example, usually, overweight or obese individuals consume too much energy and con-
sume much less fruits and vegetables [154, 155]. Lycopene is mainly contained in 
tomatoes and other vegetables or fruits, such as red carrots and watermelons. These 
findings suggest that serum lycopene levels are lower among overweight and obese indi-
viduals than normal weight individuals. However, there is not sufficient evidence to support 
this notion. Two small sample studies found a lower level of lycopene among obese indi-




significant [36, 156]. To overcome the small sample size, the data based on the third 
NHANES 1988-1994 (N=3,413) was used for studying the association between serum 
concentration of lycopene and BMI status. The authors did not report results for serum 
concentration of lycopene among normal weight, overweight and obese individuals but 
they mentioned that BMI was not associated with serum lycopene in an multivariate ad-
justed regression analysis of serum lycopene concentration [149].   
With the same dataset, Kimmons and colleagues found that the low serum lycopene 
levels (20th percentile by age and gender as the cutoff) were inversely associated with 
BMI for women and not for men [157]. Therefore, these inconsistent results may also con-
tribute to the difference criteria for the definition of “high” and “low” serum concentration 
of lycopene because no standard criteria exist for serum concentration of lycopene in the 
body. Therefore, relative serum concentration of lycopene to the amount of oxidative 
stress and/or inflammatory reaction is more rational for the definition of “high” or “low” 
serum concentration of lycopene according to self-requirement in the body. 
2.10. The Health Effects of Lycopene in Overweight and Obese Adults 
Overweight and obese individuals have an increased risk of developing metabolic syn-
drome due to subsequent chronic inflammation and oxidative stress [11, 12, 99 and 100]. 
Alleviating oxidative stress and suppressing inflammation are the main mechanisms for 
the effects of lycopene [137]. Therefore, lycopene has the potential to reduce the risk of 
metabolic syndrome by suppressing inflammation and oxidative stress in overweight and 
obese individuals.  
The health effects of lycopene on reducing inflammation and oxidative stress remain 
inconsistent in overweight and obese adults. For example, Yeon et al., McEneny et al. and 




and oxidative stress in overweight and obesity participants [32-34], while Markovits et al. 
and Thies et al. did not find a significant association between inflammation and oxidative 
stress and lycopene [36, 37]. Therefore, health effects of lycopene for individuals who are 
overweight and obese are still controversial.  
One of the potential reasons for the varying effects of lycopene is differences in the 
amount of serum lycopene in these studies. For example, in participants who were of 
similar race, age range, and BMI status, greatly increased concentrations of lycopene 
(1140 umol/L) significantly affected inflammation and/or oxidative stress [33], while a small 
increase in the cncentration of lycopene (7.61 umol/L) did not have significant effects [37]. 
Therefore, health effects of serum lycopene may also depend on the serum concentration 
of lycopene. 
Another point to consider when interpreting the research findings on lycopene is vari-
ations in the levels of oxidation and inflammation in different individuals. For example, 
based on equal serum concentrations of lycopene, it is possible that only in participants 
who have a lower BMI, lycopene can effectively reduce the levels of TNF-α and IL-8 and 
increase the levels of superoxide dismutase, glutathione peroxidase and catalase, and 
total antioxidant capacity of plasma [34, 35]. The same “high” serum concentrations of 
lycopene for individuals with a lower BMI status do not produce significant health effects 
for individuals with a higher BMI status due to increased inflammation and oxidative stress 
production [34, 35]. Therefore, health effects of serum lycopene appear to depend on the 
amount of inflammation and/or oxidative stress in the body. 
Taken together, health effects of serum lycopene depend not only on serum concen-
tration of lycopene, but also on the amount of inflammation and/or oxidative stress in the 




amount of inflammation and/or oxidative stress could better predict health effects of serum 
lycopene than with only the serum concentration of lycopene. 
2.11. Summary 
In this chapter, we first reviewed overweight/obesity, inflammation/oxidative stress and 
metabolic syndrome. Then we reviewed nutrient intake for prevention of metabolic syn-
drome, especially for lycopene. Accumulative evidence supports that lycopene can reduce 
the risk of metabolic syndrome and chronic disease. Alleviating oxidative stress and sup-
pressing inflammation are the main mechanisms for the effects of lycopene. However, the 
health effects of lycopene on reducing inflammation and oxidative stress remain incon-
sistent in overweight and obese adults. These inconsistent results may be due to different 
serum concentrations of lycopene or different amounts of inflammation and/or oxidative 
stress in the participants’ body. We hypothesized that the ratio of serum lycopene to the 
amount of inflammation and/or oxidative stress may be a better measure for analysis of 













CHAPTER 3 RESEARCH METHODS 
3.1. Overview 
This is a secondary analysis of data from a population-based cross-sectional survey 
conducted in the United States. This study used publicly available NHANES data. The 
NHANES 2001–2006 data included 15,431 participants who were at least 20 years old 
(7,341 men and 8,090 women). The outcome variables were metabolic syndrome and 
mortality. The exposure variables included serum concentration of lycopene, the ratio of 
serum lycopene to serum triglyceride and physical activity. Chi-square tests, multivariate 
logistic regressions and Cox models were used in association analyses.  
3.2. NHANES  
The NHANES is conducted by the National Center for Health Statistics of the CDC to 
assess the health and nutrition conditions of adults and children in the United States. We 
used the 2001-2006 NHANES data. The study samples included all participants aged 20 
years and older. There were 5,411 adult participants in 2001-2002, 5,041 in 2003-2004 
and 4,979 in 2005-2006. Individuals were excluded if they had missing information for 
classification of metabolic syndrome and serum concentration of lycopene. For an analy-
sis of the additive effect of physical activity and lycopene, individuals were excluded if they 
had missing information for physical activity. For a mortality analysis, individuals were ex-
cluded if they had diabetes, heart diseases and stroke history or if their underlying causes 
of death were from these conditions. Using a multistage, stratified sampling design, the 
NHANES obtains a representative sample of civilian, non-institutionalized individuals in 
the United States. In the first sample stage, researchers selected the primary sampling 
units (PSUs) from the sampling frame including all counties in the United States with PPS 




likelihood of being selected is proportionate to the size of the unit. In the second sample 
stage, researchers selected the segments from the sample frame including all census 
blocks or combined blocks in the selected PSUs in the first sample stage with PPS tech-
nique. In the third sample stage, researchers selected dwelling units (DUs) from the 
sample frame including all non-institutional group quarters in the selected segments in the 
second sample stage. To obtain reliable estimates of health and nutritional measures, 
oversampling for some subgroup populations were designed in this stage. For example, 
non-Hispanic African Americans and Mexican Americans were oversampled during 2001-
2006. In the fourth sample stage, researchers selected individuals from the list within DUs 
or households based on a previously defined probability for different race, income, gender 
and age groups [138, 158]. 
Data collections include home interviews and examinations in NHANES survey. The 
NHANES home interviews included demographic, socioeconomic, dietary, and health-re-
lated questions. A trained household interviewer administered the questionnaires in the 
sample participant’s home. The interview was conducted using a computer-assisted per-
sonal interview system and Blaise software [138, 158]. The NHANES examinations took 
place in the mobile examination center (MEC). The examination component consists of 
medical, dental, and physiological measurements, as well as laboratory tests administered 
by highly trained medical personnel. Eligibility for examination components was deter-
mined by the participant’s age and gender. The controlled environment of the MEC 
allowed physical measurements to be done under identical conditions at each survey lo-
cation [138, 158]. 
3.3. Mortality Follow-Up 
The NHANES 2001-2006 Linked Mortality File provided mortality information for par-




method of probabilistic linkage was used to trace NHANES participants with the National 
Death Index (NDI) for vital status. The linkage between survey participants and NDI can 
provide important information to conduct outcome studies, for example, in this study, the 
association between serum lycopene and mortality and the possible additive effect of 
physical activity and lycopene on mortality. 
3.4. Study Samples  
The sample for Aim 1 consisted of a total of 13,196 participants from the 2001-2006 
NHANES. Figure 2 shows how this sample was derived and categorized into three groups 
according to the serum lycopene concentration. Of the 15,431 participants of the NHANES 
2001-2006, a total of 2,235 were excluded due to missing information on metabolic syn-





























The sample for Aim 2 consisted of a total of 13,154 participants from the 2001-2006 
NHANES. Figure 3 shows how this sample was derived and categorized into three groups 
according to the ratio of serum concentration of lycopene to serum concentration of tri-
glyceride. Of the 15,431 participants of the NHANES 2001-2006, a total of 2,277 were 
excluded due to missing information on metabolic syndrome (n=1,011), BMI (n=477), se-
rum lycopene concentration (n=747), and serum triglyceride concentration (n=42).  






The sample for Aim 3 consisted of 2,496 participants from the 2001-2006 NHANES 
(Figure 4). Of the 3,868 participants with metabolic syndrome of the NHANES 2001-2006, 
a total of 1,372 were excluded due to missing information on serum lycopene concentra-
tion (n=170) and serum triglyceride concentration (n=5) or due to a history of diabetes or 
heart disease or stroke (n=1,130) or due to underlying causes of death for diabetes or 
heart disease or stroke (n=67).  





The sample for Aim 4 consisted of a total of 9,038 participants from the 2001-2006 
NHANES. Figure 5 shows how this sample was derived and categorized into three groups 
according to the ratio of serum concentration of lycopene to serum concentration of tri-
glyceride or physical activity statues. Of the 9,604 participants (BMI≥25) of the NHANES 
2001-2006, a total of 566 were excluded due to missing information on serum lycopene 
concentration (n=537), serum triglyceride concentration (n=26), and physical activity (n=3).  





The sample for Aim 5 consisted of 2,495 participants from the 2001-2006 NHANES 
(Figure 6). Of the 3,868 participants with metabolic syndrome of the NHANES 2001-2006, 
a total of 1,373 were excluded due to missing information on serum lycopene concentra-
tion (n=170), serum triglyceride concentration (n=5) and physical activity (n=1) or due to 
history with diabetes or heart disease or stroke (n=1,130) or due to underlying causes of 
death for diabetes or heart disease or stroke (n=67).  







3.5.1. Metabolic syndrome assessment and classification 
The guideline provided in the National Cholesterol Education Program’s Adult Treat-
ment Panel III report was used to identify individuals with metabolic syndrome. To be 
diagnosed with metabolic syndrome, an individual has to meet three or more of the follow-
ing criteria: abdominal obesity (waist circumference >40 inches for men and >35 inches 
for women); hypertriglyceridemia (serum triglyceride ≥1.69 mmol/L); low HDL-cholesterol 
(HDL <1.04 mmol/L for men and <1.29 for women); hypertension (≥130/85 mmHg) and 
high fasting glucose (fasting glucose ≥6.1 mmol/L) [2]. In this study, waist circumference 
(BMXWAIST), serum triglyceride (LBDSTRSI), serum HDL-cholesterol (LBDHDDSI), sys-
tolic blood pressure/ diastolic blood pressure and fasting glucose (LBDGLUSI) were used 
for classification of metabolic syndrome.  
3.5.2. BMI assessment and classification 
Overweight and obesity are conditions of excess fat accumulation in the body. BMI, 
an expression with weight divided by height squared (kg/m2), is a common measure for 
classification of overweight and obesity. An adult with a BMI less than 24.9 kg /m2 is con-
sidered to be normal weight; an adult with a BMI between 25.0 and 29.9 kg /m2 is 
considered to be overweight and an adult with a BMI of 30 kg/m2 or higher is considered 




3.5.3. Lycopene assessment and classification 
Serum concentration of trans-lycopene was measured using high-performance liquid 
chromatography with multi-wavelength photodiode-array absorbance detection. Serum tri-
glyceride was measured enzymatically by using a series of coupled reactions by Hitachi 
717 analyzer [70].  
For dietary measurement, NHANES collected two 24-hour dietary recalls for every 
participant by using the United States Department of Agriculture (USDA)’s Automated 
Multi-Pass Method. The first 24-hour recall was conducted at the MEC; the second 24-
hour recall was conducted by telephone 3-10 days later. Four data files were created from 
dietary interview information: two individual foods files and two total nutrient intake files. 
The individual foods data files include information about the types and amounts of individ-
ual foods, as well as amounts of nutrients from each food. The nutrient amounts in the 
total nutrient intake files only reflect nutrients acquired from foods and beverages reported 
by participants. The nutrient amounts in the total nutrient intake files do not include nutri-
ents from dietary supplements, medications, or plain drinking water. For example, total 
dietary lycopene only reflects intake from foods and beverages and not including any from 
dietary supplements and medications [138].  
3.5.4. Physical activity assessment and classification 
Physical activity was categorized into no physical activity, moderate physical activity 
and heavy physical activity. The categories of physical activity were defined based on the 
two questions: (1) “Over the past 30 days, did you do any vigorous activities for at least 
10 minutes that caused heavy sweating, or large increases in breathing or heart rate?” 
and (2) “Over the past 30 days, did you do moderate activities for at least 10 minutes that 




the answer to the first questions was “Yes”, participants were classified as “Heavy physical 
activity”. If the answer to the second question was “Yes” and the answer to the first ques-
tion was anything other than “Yes”, participants were classified as “Moderate physical 
activity”. If the answers to both questions were “No” or “Unable to do activity”, participants 
were classified as “No physical activity”. 
3.5.5. Alcohol consumption assessment and classification 
Alcohol consumption values were categorized based on two questions: (1) “Have you 
had at least 12 alcohol drinks/1 year?” and (2) “In the past 12 months, on those days that 
you drank alcoholic beverages, on the average, how many drinks did you have per day?” 
If the answer to the first question was “No”, participants were classified as “No alcohol 
consumption”. The alcohol consumption level was classified as “Moderate alcohol con-
sumption” if the participant answered “Yes” to the first question and “Average alcoholic 
drinks/per day less than or equate to 2 for men and less than or equate to 1 for women” 
to the second question; the alcohol consumption level was classified as “Heavy alcohol 
consumption” if the participant answered “Yes” to the first question and “Average alcoholic 
drinks/per day more than 2 for men and more than 1 for women” to the second question. 
3.5.6. Smoking assessment and classification 
Smoking status was categorized based on three questions: (1) “Have you smoked at 
least 100 cigarettes in your entire life?” (2) “Do you now smoke cigarettes?” and (3) “Dur-
ing the past 30 days, on the days that you smoked, about how many cigarettes did you 
smoke per day?” If the answer to the first question was “No”, participants were classified 
as “No smoker”; If the answer to the first question was “Yes” and the answer to the second 
question was “Not at all”, participants were classified as “Past smoker”. Smoking status 




and “Every day or some days” to the second question and “Average more than 1 cigarette 
/per day” to the third question. 
3.5.7. Assessment and classification of other variables of interest 
In this study, demographic variables included race/ethnicity (Non-Hispanic White, 
Non-Hispanic Black, Mexican American and others), gender (Male and Female), and age 
group (20–39, 40–59 and ≥60 years). Common chronic disease conditions included dia-
betes, heart disease, stroke, cancer. Diabetes was defined as answering “Yes” to the 
question “Whether a doctor told you that you had diabetes?”; and heart disease was de-
fined answering “Yes” to any of the following three questions “Has a doctor told you that 
you had coronary heart disease?” or “Has a doctor told you that you had angina/angina 
pectoris?” or “Has a doctor told you that you had heart attack?”; and stroke was defined if 
the participant answered “Yes” to the question “Has a doctor told you that you had stroke?” 
Cancer or malignancy was defined as answering “Yes” to the question “Has a doctor told 
you that you had cancer or a malignancy of any kind?” 
3.6. Missing Data 
The main purpose of this study was to examine the associations between serum lyco-
pene and metabolic syndrome or mortality. Therefore, the accuracy was very important 
for this study. Imputing a value for the missing data, such as serum concentration of lyco-
pene, could potentially introduce inaccurate values into the data. Therefore, we did not 
choose to impute a value for the missing data. We compared the sample characteristics 
between the original and the final samples. The percent of men was 47.6% in the original 
sample (15,431) and 48.0% in the final sample (13,196). The percent was 36.2% for par-
ticipants aged 20-39 years, 29.2% for participants aged 40-59 years and 34.6% for 




participants aged 20-39 years, 30.4% for participants aged 40-59 years and 33.8% for 
participants aged 60 years and older in the final sample. The prevalence of metabolic 
syndrome was 26.8% in the original sample and 27.2% in the final sample. Therefore, 
after excluding the participants with missing information, the sample characteristics did 
not change.  
3.7. Statistical Analyses 
3.7.1. Survey weights 
Statistical analyses were performed using SAS Survey Procedures (i.e., proc sur-
veyfreq and proc surveymeans) to take into account the survey clusters, strata and 
weights (SAS version 9.3, SAS Institute, Cary, NC, USA). The weighting of sample data 
was used to produce estimates of the statistics they would have obtained if the entire 
sampling frame had been surveyed. Therefore, in order to make valid statistical inferences 
for the parameters of the population, statistical analyses in this study were taken into ac-
count the survey clusters, strata and weights. 
A non-simple random sample may not represent the general population. As a complex 
multistage sample design, NHANES is a non-simple random sample. In addition, there 
are some other issues, such as non-response and non-coverage of the population in this 
study. If we estimate the population parameter with the non-weighted sample, we will get 
a biased estimation because the sample does not represent the target population. There-
fore, to make sure that a sample is representative of the target population, we should 
calculate weights for all sample units. Then, we can get an unbiased estimate for this 
population after incorporating the weights in estimating the population parameter with 




There were mainly two sample weights in NHANES for use; one was sample weights 
for in-home interview and another was sample weights for MEC exam. According to the 
rule “least common denominator” approach, we needed to select MEC exam sample 
weights because MEC exam sample weights had the least common denominator. Second, 
we needed to construct the combined sample weights for combined multi-year samples. 
We constructed the combined sample weights because we combined the samples from 
2001 to 2006 in this study. The combined sample weights= 1/3 * original sample weights 
(for 01-02, 03-04 and 05-06 survey cycles). Third, we needed to take into account of clus-
ter and strata design. For variance estimation, we also needed to take into account of 
cluster and strata for design in this study for unbiased estimation of variance with SAS 
survey procedures. Fourth, we needed to take into account of subsample analysis in the 
study; for example, we only analyzed the data for obesity and overweight adult partici-
pants. For proper estimation of variance, we needed to produce a variable for obesity and 
overweight adult participants=1, others=0; then use DOMAIN statements in the SAS sur-
vey procedure [160].   
3.7.2. Statistical analysis methods 
For Aim 1, chi-square tests were used to examine the associations between metabolic 
syndrome and race/ethnicity, gender, age and BMI status. The mean and standard devi-
ation (SD) were used for estimating serum concentration of lycopene. In addition, logistic 
regression models were performed to evaluate the association between the prevalence of 
metabolic syndrome and serum concentration of lycopene and to calculate the odds ratios 
(ORs) and 95% Confidence Intervals (CIs) after adjusting for race, gender, age group, 
alcohol consumption, smoking and physical activity.  
For Aim 2, chi-square tests were used to examine the associations between metabolic 




for estimating the ratio of serum concentration of lycopene to serum concentration of tri-
glyceride. In addition, logistic regression models were performed to evaluate the 
association between the prevalence of metabolic syndrome and the ratio of serum con-
centration of lycopene to serum concentration of triglyceride and to calculate the ORs and 
95% CIs after adjusting for race, gender, age group, alcohol consumption, smoking and 
physical activity.  
For Aim 3, chi-square tests were used to examine the associations between the ratio 
of serum concentration of lycopene to serum concentration of triglyceride and race/ethnic-
ity, gender, age group, BMI status, alcohol consumption, smoking status and physical 
activity. Chi-square tests were also used to examine the associations between the ratio of 
serum concentration of lycopene to serum concentration of triglyceride and mortality and 
disease-specific mortality. In addition, a Cox model was performed to evaluate the hazard 
ratios (HRs) and 95% CI of mortality for the ratio of serum concentration of lycopene to 
serum concentration of triglyceride adjusting for race/ethnicity, gender, age group, BMI 
status, alcohol consumption, smoking status, physical activity and cancers. Backward pro-
cedure was performed for model selection.  
For Aim 4, physical activity levels were categorized into no physical activity, moderate 
physical activity and heavy physical activity. Chi-square tests were used to examine the 
associations between physical activity and the prevalence of metabolic syndrome. To ex-
amine the effects of serum lycopene on the prevalence of metabolic syndrome, 
participants were divided into three groups by tertile ranking method according to the ratio 
of serum lycopene to serum triglyceride. Chi-square tests were used to examine the as-
sociations between serum lycopene levels (first tertile group, second tertile group and third 
tertile group) and the prevalence of metabolic syndrome. To investigate the additive effect 




square tests were used—the tests examined the associations between all combinations 
between physical activity (no physical activity, moderate physical activity and heavy phys-
ical activity) and serum lycopene levels (first, second, and third tertile groups) and the 
prevalence of metabolic syndrome for each of the BMI group. In addition, logistic regres-
sion models were performed to evaluate the associations between physical activity, serum 
lycopene levels and the prevalence of metabolic syndrome for each of the BMI group.  
ORs and 95% CIs were calculated after adjusting for race, gender, age group, alcohol 
consumption, and smoking status. The mean ratio of serum lycopene to serum triglyceride 
by physical activity was also estimated.  
For Aim 5, to examine the effect of physical activity on mortality, chi-square tests were 
used to examine the association between physical activity (no physical activity, moderate 
physical activity and heavy physical activity) and mortality. To examine the effects of se-
rum lycopene on mortality, participants were divided into three groups by tertile ranking 
method according to the ratio of serum lycopene to serum triglyceride. Chi-square tests 
were used to examine the association between serum lycopene levels and mortality. To 
investigate the additive effect of physical activity and lycopene level on mortality, Chi-
square tests were used to examine the associations between physical activity, serum ly-
copene levels and mortality. In addition, a Cox model was performed to evaluate the 
hazard ratios (HRs) and 95% CIs after adjusting for race, gender, age group, alcohol con-
sumption, smoking status. The mean ratio of serum lycopene to serum triglyceride by 
physical activity was also estimated.  
Statistical analyses were adjusted for clusters and strata of the complex sample design 
of the NHANES 2001-2006, using sample weights for aim 1, 2 and 4. Statistical analyses 




2001-2006, using sample weight for aim 3 and 5.  A two-sided P-value < 0.05 was con-
sidered to be statistically significant for all statistical analysis. 
3.8. Assumptions of the Study 
We assumed that all participants truthfully responded to the survey questions. We also 
assumed that serum concentration of lycopene and serum concentration of triglyceride 
did not change from the interview (2001-2006) to death or December 31, 2011. In addition, 
serum samples, such as serum concentration of lycopene and serum concentration of 
triglyceride, were only available at baseline; we cannot estimate the effect of changes of 
serum lycopene and serum triglyceride on the risk of mortality over time because of the 
cross-sectional design of NHANES 2001-2006. 
3.9. Summary 
The study belonged to the population-based cross-sectional study design because the 
data for this study came from the NHANES. The combination of NHANES 2001–2006 
included 15,431 participants who were at least 20 years of age (7,341 men and 8,090 
women). The main outcomes were the prevalence of metabolic syndrome and mortality. 
The main exposures were serum concentration of lycopene or the ratio of serum lycopene 
to serum triglyceride. Statistical analyses in this study were performed using SAS Survey 
Procedures (i.e., proc surveyfreq and proc surveymeans) to take into account of survey 




CHAPTER 4 RESEARCH FINDINGS 
4.1. The Influence of BMI on the Association between Serum Lycopene and the 
Prevalence of Metabolic Syndrome 
4.1.1. Demographic characteristics, BMI status, and serum lycopene level of adults with 
metabolic syndrome and those without metabolic syndrome 
Of the 13,196 participants, 3,601 (27.3%) had a diagnosis of metabolic syndrome. The 
prevalence of each metabolic syndrome condition was the following: abdominal obesity 
(50.3%; 95% CI: 48.7-51.9) hypertriglyceridemia (32.4%; 95% CI: 31.2-33.5), low HDL-
cholesterol (32.4%; 95% CI: 31.2-33.5), hypertension (30.8%; 95% CI: 29.5-32.0), and 
high fasting glucose (18.3%; 95% CI: 16.9-19.6). Demographic characteristics, the BMI 
status, and the serum lycopene level of adults with metabolic syndrome and those without 
metabolic syndrome are presented in Table 1. Individuals with metabolic syndrome tended 
to be older than those without metabolic syndrome. For example, 46.8% of those with 
metabolic syndrome were from the oldest age group (≥60 years) compared to 27.3% for 
those without metabolic syndrome. There was a significant difference in racial/ethnic char-
acteristics between these two groups. For example, the metabolic syndrome group had a 
higher proportion of Mexican Americans than the non-metabolic syndrome group (23.4% 
vs. 19.7%). The percent of metabolic syndrome was substantially increased with in-
creased BMI. Less than 10% of individuals in the metabolic syndrome group were 
classified as having a normal weight while about 40% of the non-metabolic syndrome 
group were in that category. Conversely, close to 60% of the metabolic group were in the 




mean of serum concentration of lycopene was significantly lower in participants with met-
abolic syndrome than participants without metabolic syndrome (0.38 umo/L vs. 0.42 
umo/L).  
Table 1. Demographic characteristics, BMI status, and serum lycopene level of adults with 
metabolic syndrome and those without metabolic syndrome 
Variable Metabolic Syndrome 
(N=3,601) 
No Metabolic Syndrome  
(N=9,595) 
P-value 
N % or 
Mean (SD) 
N % or 
Mean (SD) 
Age (years)      
  20-39 698 19.4 4,170 43.5 <0.0001 
  40-59 1,219 33.9 2,799 29.2 
  ≥ 60 1,684 46.8 2,626 27.3 
Sex      
  Male 1,720 47.8 4,615 48.1 0.0897 
  Female 1,881 52.2 4,980 51.9 
Race      
  NH White 1,978 54.9 4,912 51.2 <0.0001 
  NH African Ameri-
can 
550 15.3 2,065 21.5 
  Mexican American 844 23.4 1,887 19.7 
  Other 229 6.4 731 7.6 
BMI group      
  Normal weight 276 7.7 3,853 40.2 <0.0001 
  Overweight 1,258 34.9 3,461 36.1 
  Obese 2,067 57.4 2,281 23.7 
Serum lycopene 
(umol/L) 
3,601 0.38 (0.20) 9,595 0.42 (0.21) <0.0001 
NH: Non-Hispanic; N: number; SD: standard deviation. 
4.1.2. Interaction between Serum Lycopene Concentration and BMI Status  
The mean of serum concentration of lycopene was significantly lower in participants 
with metabolic syndrome than participants without metabolic syndrome. The mean serum 
concentration of lycopene was 0.206 umol/L (95% CI: 0.203-0.209) for the first tertile 
group, 0.387 umol/L (95% CI: 0.385-0.389) for the second tertile group and 0.642 umol/L 
(95% CI: 0.635-0.648) for the third tertile group. The prevalence of metabolic syndrome 




the second tertile group [25.5% (95% CI: 23.9-27.2)] and the third tertile group [22.9% (95% 
CI: 21.4-24.3)]. Table 2 shows the results of a multivariate logistic analysis. After adjusting 
for race, gender, age, alcohol consumption, smoking, physical activity and BMI status, 
there was still a significant association between metabolic syndrome and the levels of 
serum lycopene. Most importantly, there was a significant interaction effect between se-
rum lycopene and BMI status on metabolic syndrome (p<0.0001). 
Table 2. A multivariate logistic model for the association between the prevalence of met-
abolic syndrome and serum levels of lycopene 
Effect DF Wald Chi-Square P-value 
Race 3 165.19 <.0001 
Gender 1 8.10 0.0044 
Age group 2 252.45 <.0001 
Alcohol consumption 2 30.95 <.0001 
Smoking status 2 19.23 <.0001 
Physical activity 2 57.22 <.0001 
Serum lycopene 2 21.58 <.0001 
BMI 2 1370.15 <.0001 
Serum lycopene* BMI 4 31.90 <.0001 
DF: degree of freedom; BMI: body mass index. 
4.1.3. Stratification by BMI Status 
BMI is an effect modifier of the association between serum lycopene and metabolic 
syndrome. With an effect modification, a stratified analysis is an appropriate method to 
examine the association between exposure and outcome. Figure 7 shows the associations 
between serum lycopene and metabolic syndrome stratified by BMI status. For normal 
weight participants, the prevalence of metabolic syndrome was significantly lower in the 
third tertile group [3.2%, 95% CI: 2.1-4.3] compared to the first tertile group [9.8%, 95% 
CI: 7.9-11.8], and also the prevalence of metabolic syndrome was significantly lower in 
the second tertile group [3.8%, 95% CI: 2.6-4.9] compared to the first tertile group [9.8%, 
95% CI: 7.9-11.8]. For overweight participants, the prevalence of metabolic syndrome was 




first tertile group [32.2%, 95% CI: 29.3-35.0] and also the prevalence of metabolic syn-
drome was significantly lower in the second tertile group [25.0, 95% CI: 22.8-27.2] 
compared to the first tertile group [32.2%, 95% CI: 29.3-35.0]. However, for obese partic-
ipants, there was no significant difference of the prevalence of metabolic syndrome among 
the first tertile group [49.9%, 95% CI: 47.5-52.3], the second tertile group [50.1%, 95% CI: 
46.5-53.6] and the third tertile group [47.6%, 95% CI: 44.3-51.0]. 
Figure 7. The association between metabolic syndrome and serum concentration of lyco-
pene stratified by BMI status 
 
BMI: body mass index  
a The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles 
for BMI<24.9. 
b The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 3rd  tertiles 
for BMI<24.9.  
c The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles 
for BMI:25-29.9. 





After adjusting for race, gender, age, alcohol consumption, smoking and physical ac-
tivity, the associations between metabolic syndrome and serum levels of lycopene 
remained significant for participants who were normal weight or overweight (Table 3). 
Table 3. Multivariate logistic models for the associations between the prevalence of met-
abolic syndrome and serum levels of lycopene by BMI status 
BMI 
Serum Lycopene 
1st Tertile 2nd Tertile 3rd Tertile 
OR OR* 95% CI OR* 95% CI 
<24.9 1 0.56 (0.34-0.90) 0.51 (0.31-0.85) 
25-29.9 1 0.92 (0.76-1.11) 0.76 (0.59-0.97) 
≥30 1 1.07 (0.90-1.28) 1.03 (0.87-1.22) 
BMI: body mass index; OR: odds ratio; CI: confidence interval; *: Adjusted for race, gender, age, alcohol 
consumption, smoking and physical activity  
4.1.4. Stratification by serum levels of lycopene and BMI status 
We compared the mean serum concentration of lycopene and serum concentration of 
triglyceride by serum lycopene and BMI status. Table 4 shows the mean of serum con-
centration of lycopene and serum concentration of triglyceride stratified by serum levels 
of lycopene and BMI status. For normal weight participants, the mean serum concentration 
of lycopene was significantly higher in the third tertile group (0.63 umol/L) when compared 
to the first tertile group (0.20 umol/L). However, there was no significant difference of se-
rum concentration of triglyceride between the third tertile group (1.20mmol/L) and the first 
tertile group (1.33mmol/L). For overweight participants, the mean serum concentration of 
lycopene was significantly higher in the third tertile group (0.65 umol/L) when compared 
to the first tertile group (0.21 umol/L). There was no significant difference of serum con-
centration of triglyceride between the third tertile group (1.88mmol/L) and the first tertile 
group (1.77mmol/L). For obese participants, the mean serum concentration of lycopene 
was significantly higher in the third tertile group (0.64 umol/L) when compared to the first 
tertile group (0.21 umol/L). Also, the serum concentration of triglyceride was significantly 





Table 4. The mean of serum concentration of lycopene and serum concentration of triglyceride stratified by serum levels of lycopene 
and BMI status 
Tertile Label 
BMI 
<24.9 25.0-29.9 ≥30 





1,307 0.20 (0.19-0.20) 1,547 0.21 (0.20-0.21) 1,534 0.21 (0.21-0.22) 
Triglycerides  
(mmol/L) 





1,411 0.39 (0.38-0.39) 1,546 0.39 (0.38-0.39) 1,453 0.39 (0.39-0.39) 
Triglycerides  
(mmol/L) 





1,411 0.63 (0.62-0.64) 1,626 0.65 (0.64-0.66) 1,361 0.64 (0.63-0.65) 
Triglycerides  
(mmol/L) 
1,408 1.20 (1.16-1.25) 1,621 1.88 (1.74-2.01) 1,359 2.08 (1.98-2.19) 










4.2. An Association between the Lycopene to Triglyceride Ratio and the Preva-
lence of Metabolic Syndrome 
4.2.1. Demographic characteristics, BMI status, and the ratio of serum lycopene to se-
rum triglyceride of adults with metabolic syndrome and those without metabolic 
syndrome 
Of the 13,154 participants, 3,596 (27.3%) had a diagnosis of metabolic syndrome. 
Table 5 shows the demographic characteristics, BMI status, and serum lycopene level of 
adults with metabolic syndrome and those without metabolic syndrome. Individuals with 
metabolic syndrome tended to be older than those without metabolic syndrome. For ex-
ample, 46.7% of those with metabolic syndrome were in the oldest age group (≥60 years) 
compared to 27.3% for those without metabolic syndrome. There was a significant differ-
ence in racial/ethnic characteristics between these two groups. For example, the 
metabolic syndrome group had a higher proportion of Mexican Americans than the non-
metabolic syndrome group (23.4% vs. 19.7%). The percent of metabolic syndrome was 
substantially higher among overweight and obese individuals compared to those with a 
normal weight. Less than 10% of the individuals with metabolic syndrome were classified 
as having a normal weight while about 40% of the non-metabolic syndrome group were in 
that category. Conversely, close to 60% of the metabolic group were in the obese category 
while about 20% of the non-metabolic groups were in that category. The mean ratio of 
serum concentration of lycopene to serum concentration of triglyceride was significantly 







Table 5. Demographic characteristics, BMI status, and the ratio of serum lycopene to se-
















Age (years)           
  20-39 697 19.4 4,158 43.5 
<0.0001   40-59 1,219 33.9 2,789 29.2 
  ≥60 1,680 46.7 2,611 27.3 
Sex       
  Male 1,718 47.8 4,599 48.1 
0.0925 
  Female 1,878 52.2 4,959 51.9 
Race       
  NH White 1,975 54.9 4,893 51.2 
<0.0001 
  NH African Ameri-
can 
549 15.3 2,054 21.5 
  Mexican American 843 23.4 1,883 19.7 
  Other 229 6.4 728 7.6 
BMI group       
  Normal weight 276 7.7 3,837 40.1 
<0.0001   Overweight 1,254 34.9 3,449 36.1 
  Obese 2,066 57.5 2,272 23.8 
Ratio of serum lyco-
pene to serum 
triglyceride  
3,596 0.20 (0.16) 9,558 0.42 (0.31) <0.0001 
NH: Non-Hispanic; N: number; SD: standard deviation. 
4.2.2. An association between the ratio of serum lycopene to serum triglyceride and the 
prevalence of metabolic syndrome 
The mean ratio of serum lycopene to serum triglyceride was significantly lower in indi-
viduals with metabolic syndrome than individuals without metabolic syndrome. To further 
estimate the association between the prevalence of metabolic syndrome and the ratio of 
serum lycopene to serum triglyceride, three groups of participants were divided by tertile 
rank method according to the ratio of serum lycopene to serum triglyceride. The mean 
ratio of serum lycopene to serum triglyceride was 0.12 (95% CI: 0.12-0.12) for the first 
tertile group, 0.28 (95% CI: 0.28-0.29) for the second tertile group and 0.67 (95% CI: 0.66-




The prevalence of metabolic syndrome was significantly higher in the first tertile group 
[52.7% (95% CI: 50.9-54.5)] compared to the second tertile group [24.7% (95% CI: 23.1-
26.4)] and the third tertile group [7.0% (95% CI: 5.9-8.1)]. To adjust for possible confound-
ing effects, a multivariate logistic analysis was performed to evaluate the associations 
between the prevalence of metabolic syndrome and the ratio of serum lycopene to serum 
triglyceride (Table 6). After adjusting for race, gender, age, alcohol consumption, smoking, 
physical activity and BMI status, there was still a significant association between metabolic 
syndrome and the ratio of serum lycopene to serum triglyceride.  
Table 6. A multivariate logistic model for the associations between the prevalence of met-
abolic syndrome and the ratio of serum lycopene to serum triglyceride 
Effect DF Wald Chi-Square P-value 
Race 3 56.64 <.0001 
Gender 1 1.55 0.2135 
Age group 2 109.83 <.0001 
Alcohol consumption 2 15.61 0.0004 
Smoking status 2 2.82 0.2437 
Physical activity 2 16.27 0.0003 
Ratio of Serum lycopene to serum 
triglyceride 
2 425.04 <.0001 
BMI 2 546.44 <.0001 
Ratio of Serum lycopene to serum 
triglyceride *BMI 
4 16.216 0.0027 
DF: degree of freedom; BMI: body mass index. 
4.2.3. Stratification by BMI status 
To study the effect of the ratio of serum lycopene to serum triglyceride on the preva-
lence of metabolic syndrome among obese participants, associations between the ratio of 
serum lycopene to serum triglyceride and metabolic syndrome were examined with a strat-
ified analysis by BMI status (Figure 8). For each BMI status, there was a significant 
difference in the prevalence of metabolic syndrome based on the ratio of serum lycopene 
to serum triglyceride. For example, within the normal weight group, the prevalence of met-
abolic syndrome was the significantly higher among individuals in the first tertile group 




Similarly, the prevalence of metabolic syndrome was significantly higher among the sec-
ond tertile group compared to the third tertile group [0.6%, 95% CI: 0.2-1.0]. The same 
types of significant trends were observed for other BMI groups as well. 
Figure 8. The association between metabolic syndrome and the ratio of serum lycopene 
to serum triglyceride stratified by BMI status 
 
BMI: body mass index; 
a The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles 
for BMI<24.9. 
b The prevalence of metabolic syndrome was significant different (p<0.05) between the 1st  tertile and 3rd  tertile 
for BMI<24.9. 
c The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2nd  and 3rd tertile for 
BMI<24.9.  
e The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles 
for BMI:25-29.9. 
f The prevalence of metabolic syndrome was significant different (p<0.05) between the 1st  tertile and 3rd  tertile 
for BMI: 25-29.9. 
g The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2nd  and 3rd tertile for 
BMI:25-29.9.  
h The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles 
for BMI≥30. 
i The prevalence of metabolic syndrome was significant different (p<0.05) between the 1st  tertile and 3rd  tertile 
for BMI≥30. 





Multivariate logistic analyses were performed to evaluate the associations between 
the prevalence of metabolic syndrome and the ratio of serum lycopene to serum triglycer-
ide for each BMI status group (Table 7). After adjusting for race, gender, age, alcohol 
consumption, smoking and physical activity, there were still significant associations be-
tween metabolic syndrome and the ratio of serum lycopene to serum triglyceride for 
participants who were normal weight, overweight or obese. In addition, the magnitude of 
odds ratio of metabolic syndrome was lower in the 3rd tertile participants who were normal 
weight [0.035, 95% CI: 0.016-0.078] than that in participants who were obese [0.131, 95% 
CI: 0.104-0.167]. 
Table 7. Logistic models for the associations between the prevalence of metabolic syn-
drome and the ratio of serum lycopene to serum triglyceride by BMI status 
BMI 
Ratio of Serum Lycopene to Serum Triglyceride 
1st Tertile 2nd Tertile 3rd Tertile 
OR OR* 95% CI OR* 95% CI 
<24.9 1 0.243 (0.148-0.399) 0.035 (0.016-0.078) 
25-29.9 1 0.289 (0.238-0.351) 0.083 (0.062-0.112) 
≥30 1 0.359 (0.301-0.428) 0.131 (0.104-0.167) 
BMI: body mass index; OR: odds ratio; CI: confidence interval; *: Adjusted for race, gender, age, alcohol 
consumption, smoking and physical activity  
4.2.4. Stratification by serum levels of lycopene and BMI status 
With the ratio of serum concentration of lycopene to serum concentration of triglyceride, 
the mean of serum concentration of lycopene was significantly increased from the first 
tertile groups to the third tertile groups for all BMI status (Table 8). Very importantly, the 
mean of serum concentration of triglyceride was significantly decreased from the first ter-
tile groups to the third tertile groups for all BMI status. Therefore, we can get enough high 




Table 8. The mean of serum concentration of lycopene and serum concentration of triglyceride stratified by serum levels of lycopene 
and BMI status 
Rank Label 
BMI 
<24.9 25.0-29.9 ≥30 





917 0.23 (0.21-0.24) 1,673 0.30 (0.29-0.31) 1,794 0.30 (0.29-0.32) 
Triglycerides  
(mmol/L) 





1,283 0.38 (0.37-0.39) 1,580 0.44 (0.43-0.45) 1,522 0.44 (0.43-0.45) 
Triglycerides 
 (mmol/L) 





1,913 0.53 (0.52-0.54) 1,450 0.57 (0.56-0.58) 1,022 0.57 (0.56-0.59) 
Triglycerides 
 (mmol/L) 
1,913 0.82 (0.80-0.84) 1,450 0.95 (0.92-0.98) 1,022 1.00 (0.97-1.03) 




4.3. Increased Levels of Serum Lycopene is Associated with Decreased Mortality 
in People with Metabolic Syndrome 
4.3.1. Demographic characteristics of participants with metabolic syndrome by lycopene 
status 
To examine the effect of serum lycopene on survival, three groups of participants with 
metabolic syndrome were divided by tertile rank method based on the ratio of serum lyco-
pene to serum triglyceride. The mean ratio of serum concentration of lycopene to serum 
concentration of triglyceride was 0.078 (95% CI: 0.076-0.080) in the first tertile group (832 
participants), 0.167 (95% CI: 0.165-0.169) in the second tertile group (832 participants) 
and 0.365 (95% CI: 0.349-0.381) in the third tertile group (832 participants). The demo-
graphic characteristics among the three tertile groups were listed in Table 9.  
The distribution of race/ethnicity was significantly different among the three tertile 
groups. The percent of African American (21.0%) was higher in the third tertile group than 
that (9.3%) in the first tertile group while the percent of Mexican American (17.7%) was 
lower in the third tertile group than that (30.9%) in the first tertile group. The percent of 
females (52.9%) was higher in the third tertile group than that (48.0%) in the first tertile 
group. There was a lower percent of participants aged 60 years and older (30.3%) in the 
third tertile group than that (42.4%) in the first tertile group. There were no significant dif-
ferences among the groups in relation to alcohol consumption. The percent of current 
smokers (25.6%) was higher in the first tertile group than that (19.3%) in the third tertile 
group. There were a higher percentage of participants with heavy physical activity in the 






Table 9. Demographic characteristics of participants with metabolic syndrome by serum 
levels of lycopene 
   
 Variable 








 N Percent N Percent N Percent 
Race        
   NH White  433 52.0 497 59.7 464 55.8 
<0.0001 
   NH African Ameri-
can 
77 9.3 85 10.2 175 21.0 
   Mexican American 257 30.9 193 23.2 147 17.7 
   Other  65 7.8 57 6.9 46 5.5 
Gender        
   Male 433 52.0 383 46.0 392 47.1 
0.0328 
   Female 399 48.0 449 54.0 440 52.9 
Age (years)        
   20-39  181 21.8 217 26.1 249 29.9 
<0.0001    40-59  298 35.8 309 37.1 331 39.8 
   ≥60  353 42.4 306 36.8 252 30.3 
BMI group        
   Normal weight 64 7.9 38 4.7 49 6.0 
0.0006    Overweight 309 38.1 298 36.5 254 30.8 
   Obese 439 54.1 481 58.9 521 63.2 
Alcohol consumption        
   No 261 33.0 276 34.9 257 32.7 
0.5077    Moderate 304 38.4 287 36.3 280 35.6 
   Heavy 226 28.6 228 28.8 250 31.8 
Smoking        
   No 383 46.3 398 48.0 450 54.2 
0.0067    Past 233 28.1 241 29.0 221 26.6 
   Current 212 25.6 191 23.0 160 19.3 
Physical activity        
   No 416 50.0 370 44.5 317 38.1 
<0.0001    Moderate 259 31.2 267 32.1 284 34.1 
   Heavy 156 18.8 195 23.4 231 27.8 
NH: Non-Hispanic; N: number; BMI: body mass index. 
4.3.2. Mortality by lycopene status in adults with metabolic syndrome 
The NHANES 2001-2006 Linked Mortality File provided mortality information for par-
ticipants involved in NHANES interview (2001-2006) through December 31, 2011. Of the 
832 participants with metabolic syndrome in the first tertile group, 83 participants had died. 
Of the 832 participants with metabolic syndrome in the second tertile group, 50 partici-
pants had died. Of the 832 participants with metabolic syndrome in the third tertile group, 




tertile group (5.2%, 95% CI: 3.7-6.7) or in the second tertile group (6.0%, 95% CI: 4.4-7.6) 
compared to the first tertile group (10.0%, 95% CI: 7.9-12.0) among participants with met-
abolic syndrome.  
4.3.3. An association between the serum lycopene and mortality in adults with metabolic 
syndrome 
We conducted a Cox model to estimate the hazard ratios (HR) and 95% CI of mortality 
adjusting for race, gender, age groups, BMI status, smoking status, alcohol consumption, 
physical activity and cancers. The final model included race, age group, BMI status, smok-
ing status, physical activity and serum levels of lycopene. Compared with the first tertile 
group (HR=1.0), both the third tertile (HR=0.63, 95% CI: 0.43-0.91) and the second tertile 
groups (HR=0.63, 95% CI: 0.43-0.94) had a significantly lower hazard ratios of mortality 
for participants with metabolic syndrome after adjusting for these variables (Table 10).   
Table 10. Cox models for the associations between mortality and serum levels of lycopene 
for participants with metabolic syndrome  
Serum Lycopene Hazard Ratio* 95% CI 
1st tertile 1.0 N/A 
2nd tertile 0.63 (0.43-0.94) 
3rd tertile  0.63 (0.43-0.91) 
CI: confidence interval; N/A: not applicable; *Adjusted for race, gender, age groups, BMI status, smoking 
status, alcohol consumption, physical activity and cancers. 
 
4.4. An Additive Effect of Physical Activity and Serum Lycopene on the Prevalence 
of Metabolic Syndrome among Overweight and Obese Adults 
4.4.1. Independent effect of physical activity 
Of the 9,038 participants who were overweight or obese, there were 3,319 (36.7%) 
participants with metabolic syndrome. The prevalence of metabolic syndrome varied ac-




in participants with heavy physical activity (26.8%, 95% CI 24.9-28.7) was significantly 
lower compared to participants with no physical activity (43.3%, 95% CI 41.4-45.2).  
4.4.2. Independent effect of serum lycopene 
To estimate the association between the prevalence of metabolic syndrome and the 
ratio of serum lycopene to serum triglyceride, participants were divided by tertile rank 
method according to the ratio of serum lycopene to serum triglyceride. The mean ratio of 
serum lycopene to serum triglyceride was 0.107 (95% CI: 0.105-0.109) for the first tertile 
group, 0.249 (95% CI: 0.246-0.252) for the second tertile group and 0.592 (95% CI: 0.580-
0.605) for the third tertile group. There was a significantly dose-dependent decrease the 
percent of metabolic syndrome from the first tertile group (63.2%, 95% CI: 61.2-65.2), the 
second tertile group (38.6%, 95% CI: 36.6-40.5) to the third tertile group (13.8%, 95% CI: 









Figure 9. The association between metabolic syndrome and physical activity or the ratio 
of serum lycopene to serum triglyceride 
 
#  The prevalence of metabolic syndrome was significantly different (p<0.05) between the no physical activity 
and heavy physical activity. 
a The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles. 
b The prevalence of metabolic syndrome was significant different (p<0.05) between the 1st  tertile and 3rd  tertile. 
c The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2nd  and 3rd tertile.  
4.4.3. An additive effect of physical activity and serum lycopene 
To estimate the additive effect of physical activity and serum lycopene on the preva-




of serum lycopene. There was a significant interaction effect between the combined phys-
ical activity and serum lycopene and BMI status on the prevalence of metabolic syndrome. 
BMI is an effect modifier of the association between the combined physical activity and 
serum lycopene and metabolic syndrome. Therefore, we showed the additive effects of 
physical activity and serum lycopene stratified by BMI status, overweight and obesity (Ta-
ble 11). 
For overweight participants, the prevalence of metabolic syndrome was significantly 
reduced with increased levels of serum lycopene for all physical activity levels. For exam-
ple, the prevalence of metabolic syndrome reduced from 54.3% in the first tertile to 11.6% 
in the third tertile for participants without physical activity. The prevalence of metabolic 
syndrome reduced from 53.5% in the first tertile to 8.6% in the third tertile for participants 
with moderate physical activity. The prevalence of metabolic syndrome reduced from 39.0% 
in the first tertile to 2.6% in the third tertile for participants with heavy physical activity.  
The prevalence of metabolic syndrome was significantly reduced in participants with 
heavy physical activity compared to participants without physical activity for all levels of 
serum lycopene. For example, in the first tertile, the prevalence of metabolic syndrome 
reduced from 54.3% among participants without physical activity to 39.0% among partici-
pants with heavy physical activity. In the second tertile, the prevalence of metabolic 
syndrome reduced from 23.9% among participants without physical activity to 15.1% 
among participants with heavy physical activity. In the third tertile, the prevalence of met-
abolic syndrome reduced from 11.6% among participants without physical activity to 2.6% 
among participants with heavy physical activity. Therefore, there was an additive effect of 




 For obese participants, the prevalence of metabolic syndrome was still significantly 
reduced with increased levels of serum lycopene for all physical activity status. For exam-
ple, the prevalence of metabolic syndrome reduced from 69.6% in the first tertile to 19.8% 
in the third tertile for participants without physical activity. The prevalence of metabolic 
syndrome reduced from 73.8% in the first tertile to 24.0% in the third tertile for participants 
with moderate physical activity. The prevalence of metabolic syndrome reduced from 68.3% 
in the first tertile to 21.5% in the third tertile for participants with heavy physical activity.  
However, the prevalence of metabolic syndrome was not significantly different be-
tween participants with heavy physical activity and participants without physical activity for 
all levels of serum lycopene. For example, in the first tertile, the prevalence of metabolic 
syndrome was not different between participants without physical activity (69.6%) and 
participants with heavy physical activity (68.3%). In the second tertile, the prevalence of 
metabolic syndrome was not different between participants without physical activity 
(46.2%) and participants with heavy physical activity (42.2%). In the third tertile, the prev-
alence of metabolic syndrome was not different between participants without physical 
activity (19.8%) and participants with heavy physical activity (21.5%).Therefore, there was 
no an additive effect of physical activity and serum lycopene on metabolic syndrome.  
Table 11. The prevalence of metabolic syndrome by the combination of the levels of phys-








1st Tertile 2nd Tertile 3rd Tertile 
% 95% CI % 95% CI % 95% CI 
Overweight 
None 54.3 (49.0-59.7) 23.9 (19.7-28.2) 11.6 (7.5-15.7) 
Moderate  53.5 (48.1-59.0) 27.9 (23.8-32.1) 8.6 (5.1-12.1) 
Heavy  39.0 (33.1-45.0) 15.1 (10.8-19.4) 2.6 (1.3-3.9) 
Obesity 
None 69.6 (65.9-73.2) 46.2 (41.6-50.9) 19.8 (13.7-25.9) 
Moderate  73.8 (69.5-78.1) 45.2 (39.5-51.0) 24.0 (18.6-29.5) 
Heavy  68.3 (62.9-73.6) 42.2 (36.2-48.3) 21.5 (15.1-27.9) 




4.4.4. Logistic regression results 
Logistic regression analyses were performed to evaluate the association between the 
prevalence of metabolic syndrome and the combination of the levels of physical activity 
and the levels of serum lycopene, and to calculate the ORs and 95% CI. Table 12 show 
the ORs and 95%CI after adjusting for race, gender, age group, alcohol consumption and 
smoking status in the risk of metabolic syndrome (Table 12).  
For overweight participants, after adjusting for race, gender, age group, alcohol con-
sumption and smoking status, the magnitude of OR was significantly reduced with 
increased levels of serum lycopene for all physical activity levels. For example, the mag-
nitude of OR reduced from 1 in the first tertile to 0.12 (95% CI: 0.07-0.19) in the third tertile 
for participants without physical activity. The magnitude of OR reduced from 0.94 (95% CI: 
0.67-1.32) in the first tertile to 0.08 (95% CI: 0.05-0.13) in the third tertile for participants 
with moderate physical activity. The magnitude of OR reduced from 0.65 (95% CI: 0.47-
0.90) in the first tertile to 0.03 (95% CI: 0.02-0.06) in the third tertile for participants with 
heavy physical activity. The magnitude of OR was also significantly reduced with in-
creased level of physical activity for serum lycopene levels. For example, in the first tertile, 
the magnitude of OR reduced from 1 among participants without physical activity to 0.65 
(95% CI: 0.47-0.90) among participants with heavy physical activity. In the third tertile, the 
magnitude of OR reduced from 0.12 (95% CI: 0.07-0.19) among participants without phys-
ical activity to 0.03 (95% CI: 0.02-0.06) among participants with heavy physical activity. 
Therefore, therefore, there was an additive effect of physical activity and serum lycopene 
on metabolic syndrome. 
For obese participants, after adjusting for race, gender, age group, alcohol consump-
tion and smoking status, the magnitude of OR was significantly reduced with increased 




reduced from 1 in the first tertile to 0.12 (95% CI: 0.08-0.17) in the third tertile for partici-
pants without physical activity. The magnitude of OR reduced from 1.16 (95% CI: 0.87-
1.56) in the first tertile to 0.15 (95% CI: 0.11-0.22) in the third tertile for participants with 
moderate physical activity. The magnitude of OR reduced from 0.92 (95% CI: 0.67-1.27) 
in the first tertile to 0.14 (95% CI: 0.09-0.20) in the third tertile for participants with heavy 
physical activity. However, the magnitude of OR was not significantly different between 
participants with heavy physical activity and participants without physical activity for all 
levels of serum lycopene. For example, in the first tertile, the magnitude of OR was not 
different between participants without physical activity (1) and participants with heavy 
physical activity (0.92, 95% CI: 0.67-1.27). In the second tertile, the magnitude of OR was 
not different between participants without physical activity (0.37, 95% CI: 0.28-0.50) and 
participants with heavy physical activity (0.35, 95% CI: 0.26-0.47). In the third tertile, the 
magnitude of OR was not different between participants without physical activity (0.12, 95% 
CI: 0.08-0.17) and participants with heavy physical activity (0.14, 95% CI: 0.09-0.20). 
Therefore, there was no an additive effect of physical activity and serum lycopene on met-
abolic syndrome. 
Table 12. Multivariate logistic models for the associations between the prevalence of met-
abolic syndrome by the combination of the levels of physical activity and the levels of 





1st Tertile 2nd Tertile 3rd Tertile 
OR* 95% CI OR* 95% CI OR* 95% CI 
 
Overweight 
None 1 N/A 0.28 (0.19-0.39) 0.12 (0.07-0.19) 
Moderate  0.94 (0.67-1.32) 0.29 (0.21-0.42) 0.08 (0.05-0.13) 
Heavy  0.65 (0.47-0.90) 0.18 (0.12-0.26) 0.03 (0.02-0.06) 
 
Obesity 
None 1 N/A 0.37 (0.28-0.50) 0.12 (0.08-0.17) 
Moderate  1.16 (0.87-1.54) 0.38 (0.29-0.51) 0.15 (0.11-0.22) 
Heavy  0.92 (0.67-1.27) 0.35 (0.26-0.47) 0.14 (0.09-0.20) 
BMI: body mass index; OR: odds ratio; CI: confidence interval; N/A: not applicable; * Adjusted for race, gender, 




4.4.5. The mean ratio of serum lycopene to serum triglyceride by physical activity 
The mean ratio of serum lycopene to serum triglyceride was significantly higher in 
participants with heavy physical activity than participants without physical activity for all 
BMI status (Table 13). For example, among overweight participants, the ratio increased 
from 0.31 (95% CI: 0.30-0.33) in participants with no physical activity to 0.42 (95% CI: 
0.40-0.44) in participants with heavy physical activity. For example, among obese partici-
pants, the ratio increased from 0.27 (95% CI: 0.25-0.28) in participants with no physical 
activity to 0.34 (95% CI: 0.33-0.36) in participants with heavy physical activity. The mean 
ratio of serum lycopene to serum triglyceride was significantly higher with increased levels 
of physical activity.  
Table 13. The mean ratio of serum lycopene to serum triglyceride by physical activity  
BMI Status Physical Activity N 
Mean Ratio of Serum 




None 1,883 0.31 (0.30-0.33) 
Moderate 1,414 0.35 (0.33-0.37) 
Heavy 1,403 0.42 (0.40-0.44) 
Obesity 
None 1,936 0.27 (0.25-0.28) 
Moderate 1,366 0.29 (0.28-0.31) 
Heavy 1,036 0.34 (0.33-0.36) 
BMI: body mass index; N: number; CI: confidence interval. 
 
4.5. An Additive effect of Physical Activity and Serum Lycopene on Mortality in 
Adults with Metabolic Syndrome 
4.5.1. The mortality among adults with metabolic syndrome by physical activity 
The combination of NHANES 2001–2006 included 3,868 participants who were at 
least 20 years of age with metabolic syndrome. Participants who had missing information 
on serum lycopene and serum triglyceride and physical activity (n=176) were excluded. In 




died from diabetes or heart disease or stroke (n=67) were excluded. As a result, the final 
sample included 2,495 individuals. 
The percent of individuals who had died was significantly reduced in participants with 
heavy physical activity (3.1%) compared to the participants with no physical activity (9.3%) 
(Table 14). 
Table 14. The percentage of individuals with metabolic syndrome who had died: Stratifi-
cation by physical activity level 
Physical Activity N % of Individuals Died 95% CI 
None 1,103 9.3 (7.6-11.1) 
Moderate  810 6.7 (4.9-8.3) 
Heavy  582 3.1 (1.7-4.5) 
N: number; CI: confidence interval. 
4.5.2. Mortality by the levels of serum lycopene among adults with metabolic syndrome 
To examine the effect of serum lycopene on death, participants with metabolic syn-
drome were divided by tertile rank method based on the ratio of serum lycopene to serum 
triglyceride. The mean ratio of serum lycopene to serum triglyceride was 0.078 (95% CI: 
0.076-0.080) in the first tertile group, 0.167 (95% CI: 0.165-0.169) in the second tertile 
group and 0.365 (95% CI: 0.349-0.381) in the third tertile group. The proportion of individ-
uals who had died was significantly reduced in the third tertile group (5.2%) compared to 
the first tertile group (9.9%) among participants with metabolic syndrome (Table 15). 
Table 15. The percentage of individuals with metabolic syndrome who had died: Stratified 
by serum lycopene levels 
Serum Lycopene  N % of Individuals Died 95% CI 
1st tertile  831 9.9 (7.8-11.9) 
2nd  tertile  832 6.0 (4.4-7.6) 
3rd  tertile  832 5.2 (3.7-6.7) 




4.5.3. Mortality by physical activity and serum lycopene among adults with metabolic 
syndrome 
Due to the second tertile group and the third tertile group having similar mortality rate, 
we combined these two groups. The proportion of individuals who died was significantly 
reduced in participants with higher levels of serum lycopene and heavy physical activity 
(2.8%, 95% CI: 1.2-4.4) compared to participants with higher levels of serum lycopene 
and no physical activity (7.7%, 95% CI: 5.7-9.7) (Table 16). The proportion of individuals 
who had died was similar between participants with higher levels of serum lycopene and 
heavy physical activity (2.8%, 95% CI: 1.2-4.4) and participants with lower levels of serum 
lycopene and heavy physical activity (3.8%, 95% CI: 0.8-6.8).  
Table 16. The proportion of individuals who had died in metabolic syndrome by physical 
activity and serum lycopene levels 
Physical Activity 
Serum Lycopene 
1st  Tertile 2nd and 3rd  Tertile 
N % Died 95% CI N % Died 95% CI 
None 416 12.0 (8.9-15.1) 687 7.7 (5.7-9.7) 
Moderate 259 10.0 (6.4-13.7) 551 5.1 (3.2-6.9) 
Heavy 156 3.8 (0.8-6.8) 426 2.8 (1.2-4.4) 
N: number; CI: confidence interval. 
4.5.4. Additive effects of physical activity and serum lycopene on mortality among adults 
with metabolic syndrome 
We conducted Cox analyses to estimate hazard ratios and 95% CIs of mortality after 
adjusting for race, gender, age, smoking status, alcohol consumption (Table 17). There 
was a significant effect of serum lycopene on mortality for participants with metabolic syn-
drome. However, there was no a significant additive effect of physical activity and serum 





Table 17. Hazard ratios (HRs) and 95% CI of mortality in metabolic syndrome by combing 
of physical activity and lycopene levels in the multivariate logistic regression models 
Physical Activity 
Serum Lycopene Level 
1st Tertile 2nd & 3rd Tertiles 
HR* 95% CI HR* 95% CI 
None 1 N/A 0.651 (0.430-0.985) 
Moderate  0.663 (0.398-1.106) 0.395 (0.241-0.650) 
Heavy  0.506 (0.215-1.194) 0.317 (0.162-0.621) 
CI: confidence interval. 
4.5.5. The mean ratio of serum lycopene to serum triglyceride by physical activity among 
adults with metabolic syndrome 
The mean ratio of serum lycopene to serum triglyceride was significantly higher in 
participants with heavy physical activity than participants without physical activity (Table 
18). For example, the ratio increased from 0.19 (95% CI: 0.18-0.20) in participants without 
physical activity to 0.23 (95% CI: 0.22-0.24) in participants with heavy physical activity.  
Table 18. The mean ratio of serum lycopene to serum triglyceride by physical activity 
Physical Activity N 
Mean of Ratio of Serum 
Lycopene to Serum Tri-
glyceride 
95% CI 
None 1,103 0.19 (0.18-0.20) 
Moderate  810 0.22 (0.20-0.23) 
Heavy  582 0.23 (0.22-0.24) 
N: number; CI: confidence interval. 
4.6. Summary of Findings 
In this chapter, we presented the main findings from the analyses of NHANES data. 
First, we found that BMI had an important influence on the association between serum 
lycopene and metabolic syndrome. A higher serum concentration of lycopene was signif-
icantly associated with a lower prevalence of metabolic syndrome. However, these 
associations were only significant for normal weight and overweight participants, but not 




serum triglyceride and the prevalence of metabolic syndrome was significant not only for 
normal weight and overweight participants, but also for obese participants.  
Thirdly, a high level of serum lycopene was significantly associated with a decreased 
mortality among participants with metabolic syndrome. Metabolic syndrome participants 
with a higher level of serum lycopene (the mean ratio of serum lycopene to serum triglyc-
eride=0.364) had a significantly smaller proportion of death (p<0.0001) than those with a 
lower level of serum lycopene (the mean ratio=0.077). Even after adjusting for race, age, 
BMI status, smoking and physical activity, metabolic syndrome participants with a higher 
level of serum lycopene still had a significantly reduced hazard ratio of mortality than those 
with a lower level of serum lycopene (p<0.05). Fourthly, physical activity and serum lyco-
pene had an additive effect on the prevalence of metabolic syndrome for overweight 
individuals but not for obese individuals. Fifthly, there was not an additive effect of physical 




CHAPTER 5 DISCUSSION 
5.1. Discussion 
5.1.1. Health effects of lycopene on obese individuals 
Metabolic syndrome is an important public health issue. About one in three United 
States adult aged 20 years and older has metabolic syndrome [2]. Metabolic syndrome is 
a direct risk factor for chronic diseases, such as cardiovascular diseases, diabetes melli-
tus, stroke and cancers [1, 3-5 and 160]. The growing prevalence of metabolic syndrome 
is strongly related to the increasing prevalence of overweight and obesity [2, 12]. There-
fore, preventing overweight and obesity is an important strategy to reduce the prevalence 
of metabolic syndrome. However, interventions related to overweight and obesity have not 
achieved expected results; more than one-third of adults and 17% of youth in the United 
States are obese [75]. Therefore, reducing the development of metabolic syndrome in 
individuals who are overweight and obese may be an innovative approach to reduce the 
total burden of chronic diseases in the general population. 
As a natural nutrient, the higher level of lycopene is significantly associated with the 
lower prevalence of metabolic syndrome in the general population [23-25]. The biological 
mechanisms by which lycopene reduces the risk of metabolic syndrome include alleviating 
oxidative stress and decreasing inflammation [18-22, 126]. Studies show that the in-
creased risk of metabolic syndrome in individuals who are overweight and obese 
contributes to increased inflammation and oxidative stress production [11, 13 and 161]. 
Therefore, increasing serum concentration of lycopene is a potential strategy to decrease 
the risk of developing metabolic syndrome in individuals who are overweight and obese. 




not clear whether lycopene has similar effects among individuals who are overweight or 
obese. 
For this reason, recently, more studies about the health effects of lycopene began to 
focus on individuals who were overweight and obese [32-37]. However, the findings from 
these studies have been inconclusive. There are two potential reasons for conflicting re-
sults among the studies: one potential reason is that the participants had different BMI 
levels [34, 35], and the other reason is that the participants had different serum concen-
trations of lycopene [33, 37].  
The same “high” serum concentrations of lycopene for individuals with a lower BMI 
level may not produce the same health effects in individuals with a higher BMI level be-
cause there is more inflammation and oxidative stress production in individuals who are 
obese or overweight [34, 35]. Our results strongly supported the idea that with the same 
serum concentration of lycopene, lycopene is significantly associated with the prevalence 
of metabolic syndrome only for normal weight and overweight individuals, but not for 
obese individuals. The biological mechanisms by which lycopene reduces the risk of met-
abolic syndrome mainly depend on alleviating oxidative stress and decreasing 
inflammation [18-22, 126]. Therefore, the effects of lycopene on alleviating oxidative stress 
and decreasing inflammation may predict the effects of lycopene on metabolic syndrome. 
With the same level of serum concentrations of lycopene, the effects of serum lycopene 
on the prevalence of metabolic syndrome are only significant for normal weight or over-
weight individuals, not for obese individuals. 
However, accumulating evidence also supports that lycopene inhibited inflammation 
and oxidative stress in a dose-dependent manner [38, 39]. Therefore, we hypothesized 
that highly efficient serum concentration of lycopene may be needed to produce significant 




the study, the serum concentration of lycopene was relatively low among obese partici-
pants (0.642 umol/L in the third tertile group) which was also the same as the serum 
concentration of lycopene among normal weight participants (0.642 umol/L in the third 
tertile group). In a future observational study, a new analysis method for serum lycopene 
(for example, relative serum lycopene to the amount of inflammation and oxidative stress 
in the body) may be used to confirm the hypothesis. 
5.1.2. The ratio of serum lycopene to serum triglyceride can predict the health effect of 
lycopene on metabolic syndrome 
Health effects of serum lycopene depend not only on the serum concentration of lyco-
pene, but also on the amount of inflammation and/or oxidative stress in the body; 
therefore, we hypothesized that the ratio of serum concentration of lycopene to the amount 
of inflammation and/or oxidative stress could better predict the association between serum 
lycopene and the health effects. There is no method to directly measure the amount of 
inflammation and/or oxidative stress in the body. Given the strong associations between 
oxidative stress [41] and inflammation [42], this study used serum triglyceride to represent 
the amount of inflammation and/or oxidative stress.   
To verify our hypothesis, we examined the association between the ratio of serum 
concentration of lycopene to serum concentration of triglyceride and the prevalence of 
metabolic syndrome. As expected, our study showed that higher ratios of serum concen-
tration of lycopene to serum concentration of triglyceride were significantly associated with 
the reduced prevalence of metabolic syndrome. This result is consistent with findings of 
previous studies with serum concentration of lycopene as exposure [23-25]. Furthermore, 
the association between the ratio of serum lycopene to serum triglyceride and the preva-
lence of metabolic syndrome is significant not only for normal weight and overweight 




5.1.3. Comparison of two methods for the association between serum lycopene and met-
abolic syndrome 
We compared the associations between metabolic syndrome and lycopene with dif-
ferent measures of serum lycopene: serum concentration of lycopene and the ratio of 
serum concentration of lycopene to serum concentration of triglyceride. With the serum 
concentration of lycopene, the association between metabolic syndrome and lycopene 
was significant only for normal weight and overweight participants, not for obese partici-
pants. With the ratio, the association between metabolic syndrome and lycopene was 
significant not only for normal weight and overweight participants, but also for obese par-
ticipants. What caused the different results? We hypothesized that the different results 
may be related to the difference in levels of inflammation and oxidative stress between 
normal weight/overweight participants and obese participants. Therefore, we compared 
the mean serum concentrations of lycopene and serum concentrations of triglyceride 
among all combination of serum levels of lycopene and BMI. 
With serum concentration of lycopene (Table 4), the mean serum concentration of 
lycopene was significantly increased from the first tertile group to the third tertile group for 
all BMI levels while the mean serum concentration of triglyceride was different among the 
three BMI levels. The mean serum concentrations of triglyceride was not significantly dif-
ferent between the third tertile group and the first tertile group for normal weight and 
overweight participants while the mean serum concentration of triglyceride was signifi-
cantly different between the third tertile group and the first tertile group for obese 
participants. Therefore, the serum concentrations of lycopene considered to be “high” for 
individuals with a lower BMI does not produce the same health effects in individuals with 
a higher BMI because there is more inflammation and oxidative stress production in peo-




With the ratio of serum concentration of lycopene to serum concentration of triglyceride 
(Table 8), the situation is different. The mean serum concentration of lycopene was sig-
nificantly increased from the first tertile group to the third tertile group for all BMI levels.  
Also, the mean serum concentration of triglyceride was significantly decreased from the 
first tertile group to the third tertile group for all BMI levels. Therefore, the ratio method can 
provide the same conditions (with similar serum concentration of lycopene and serum 
concentration of triglyceride) for all BMI levels. This may mean that health effects of lyco-
pene are significant not only for normal weight and overweight participants, but also for 
obese individuals. 
In addition, with the serum concentration of lycopene (Table 4), the health effects of 
lycopene were not different between the second tertile group and third tertile group for 
normal weight and overweight participants. However, the plateau effect of lycopene may 
be an alternative explanation—it is possible that the serum lycopene was not high enough 
in the third tertile group when compared to the second tertile group. With the ratio of serum 
lycopene to serum triglyceride (Table 8), the health effects of lycopene were significantly 
different between the second tertile group and third tertile group for all BMI levels because 
there was a relatively higher concentration of serum lycopene in the third tertile group than 
in the second tertile group. Therefore, consistent with findings of previous studies [38, 39], 
this study showed that there is a biologically gradient relationship between the ratio of 
serum lycopene to serum triglyceride and metabolic syndrome.  
The findings of this study indicate that if the relative level of serum lycopene, according 
to the amount of inflammation and/or oxidative stress, is higher, then serum lycopene may 
produce significant health effects no matter what the actual serum concentration of lyco-
pene is. This means that a high level of serum lycopene could have significant health 




5.1.4. The health effect of lycopene on mortality among individuals with metabolic syn-
drome 
Serum lycopene can reduce the prevalence of metabolic syndrome among adults. 
However, whether serum lycopene still has positive health effects among individuals who 
have developed a health condition with metabolic syndrome is not clear. We hypothesized 
that serum lycopene can reduce the mortality in individuals with metabolic syndrome. 
To test our hypothesis, we examined the health effect of serum lycopene on mortality 
among NHANES participants with metabolic syndrome. As expected, our study clearly 
showed that the higher level of serum lycopene was significantly associated with the lower 
mortality among participants with metabolic syndrome. Therefore, even if individuals who 
have been classified as having metabolic syndrome, serum lycopene can still help reduce 
the risk of mortality for them. 
5.1.5. The additive health effects of physical activity and lycopene on morbidity of meta-
bolic syndrome 
In addition to lycopene, physical activity can reduce the risk of metabolic syndrome 
[43-45]. However, the effects of physical activity or lycopene alone are insufficient to sub-
stantially reduce the risk of metabolic syndrome for overweight and obese individuals [44]. 
Therefore, exploring the additive effects between physical activity and serum lycopene is 
important for further reducing the risk of metabolic syndrome among individuals who are 
overweight and obese.  
Our results showed that the additive effects of physical activity and serum lycopene 
differs by the BMI level. The additive effect was only found among overweight individuals 
but not for obese individuals. There are two potential explanations for the different effects 




overweight individuals and obese individuals. One explanation is that physical activity re-
duces the prevalence of metabolic syndrome among obese individuals mainly through 
other means, such as weight control and an increased level of serum lycopene. Research 
has shown that physical activity has complex mechanisms on the prevalence of metabolic 
syndrome, such as controlling weight [162], reducing serum concentration of triglyceride, 
increasing high-density lipoprotein, improving insulin sensitivity, reducing blood pressure 
and decreasing inflammation reactions and inducting an anti-inflammatory environment 
[46-48]. Our results indicated that the increasing the level of serum lycopene may be one 
of the mechanisms by which physical activity reduces the risk of metabolic syndrome. 
Consistent with this hypothesis, Cheriyath et al. found that body weight is a more important 
determinant than physical activity in the development of metabolic syndrome [44]. There-
fore, the additive effect of physical activity and serum lycopene among obese individuals 
may need to be analyzed using more complex conceptual and analytical models that in-
clude weight control and serum lycopene change.  
Another explanation is that self-reported physical activity is less accurate among 
obese individuals than normal weight and overweight individuals. Serum lycopene is an 
objective variable, while physical activity is a subjective variable in this study. Inaccurate 
self-reported physical activity will lead to misclassifications. Accumulating evidence sup-
ports that obese participants overestimate their vigorous physical activity levels and 
misclassify the intensity of physical activity than normal weight and overweight participants 
[163-165]. This means that the misclassification of physical activity is unrelated to classi-
fication of metabolic syndrome. As a result, the misclassification of physical activity is a 
non-differential misclassification, which may have led to results toward the null for obese 




  5.1.6. The additive health effects of physical activity and lycopene on mortality of meta-
bolic syndrome 
For mortality, consistent with the previous findings, physical activity is significantly as-
sociated with reduced mortality in patients with metabolic syndrome [69]. Our results also 
showed that higher serum lycopene levels are significantly associated with reduced mor-
tality in participants with metabolic syndrome. We did not find a significant additive effect 
of physical activity and serum lycopene on mortality for participants with metabolic syn-
drome. However, increasing serum levels of lycopene may be one of the mechanisms by 
which physical activity reduces the risk of mortality among individuals with metabolic syn-
drome. 
In summary, our findings support our conceptual model (Figure 10). Serum lycopene 
and physical activity can decrease the risk of metabolic syndrome among adults. Serum 
lycopene and physical activity have an additive effect on metabolic syndrome for over-
weight individuals, not for obese individuals. Serum lycopene and physical activity can 
significantly decrease the risk of mortality among individuals with metabolic syndrome. 
Serum lycopene and physical activity do not have an additive effect on reducing mortality 
among individuals with metabolic syndrome. However, increased serum lycopene may be 
one of the mechanisms by which physical activity reduces the risk of morbidity and mor-







Figure 10. A conceptual model linking lycopene, physical activity, overweight/obesity, met-
abolic syndrome and mortality 
 
5.2. Strengths and Limitations of the Study 
Strengths of this study include a large and representative sample and well-character-
ized data with many potential risk factors. First, we found that there was a significant 
interaction effect between serum lycopene and BMI status on metabolic syndrome. There-
fore, BMI was an effect modifier of the association between serum lycopene and metabolic 
syndrome. With effect modification, stratified analysis is an appropriate method to exam-
ine the association between exposure and outcome. Therefore, the association between 
serum lycopene and metabolic syndrome was analyzed separately for normal weight, 
overweight and obese participants in this study. Secondly, the health effect of serum ly-
copene on the prevalence of metabolic syndrome may depend not only on serum 




therefore, we use the ratio of serum concentration of lycopene to the amount of inflamma-
tion and/or oxidative stress as a new measure of lycopene in this study. Our result also 
supports the idea that the ratio of the serum concentration of lycopene to the amount of 
inflammation and/or oxidative stress can better predict the association between lycopene 
and positive health effects than only with serum concentration of lycopene. 
 Limitations of the study should be also noted. First, as stated previously, a self-report 
may have produced non-differential and differential misclassification of physical activity 
levels and other variables. Secondly, although there were strong and dose-response as-
sociations between lycopene and the morbidity and mortality of metabolic syndrome, it is 
not possible to show a causal inference between serum lycopene and metabolic syndrome 
due to the cross-sectional nature of the study. Thirdly, the effect of serum lycopene may 
be underestimated in the present study because serum lycopene may be higher in clinical 
trials when subjects take more fruits and vegetables rich in lycopene or more lycopene 
supplement than in the current study. Lastly, the effect of changes of serum lycopene on 
the risk of mortality over time could not be analyzed because of the cross-sectional design 
of NHANES.  
5.3. Conclusion 
From a nationally representative sample of the United States adults, our study adds 
new evidence that the ratio of serum lycopene to serum triglyceride has significant asso-
ciations with morbidity and mortality of metabolic syndrome. However, due to some 
limitations of the study, the findings from the study cannot directly provide clinical recom-
mendations, but can provide a new analysis method for future studies between lycopene 




5.4. Suggestions for the Future Research 
Due to being a part of a cross-sectional study, the current study is difficult to build a 
causal inference between serum lycopene and metabolic syndrome. Further prospective 
studies with the incidence of metabolic syndrome are needed to confirm these primary 
results. For example, a cohort of participants may be randomly selected from a commu-
nity. Then, these participants may be randomly assigned into three groups, a control 
group, a low-tomato diet and a high-tomato diet. These participants could be followed-up 
for around 10 years and periodically tested for serum concentration of lycopene and serum 
concentration of triglyceride and estimated metabolic syndrome condition. Then, we could 
estimate the causal effect of serum lycopene on the incidence of metabolic syndrome.  
According to our findings, even among obese individuals, if the relative level of serum 
lycopene according to the amount of inflammation and/or oxidative stress is higher, serum 
lycopene may produce significant health effects no matter what actual serum concentra-
tion of lycopene is. Therefore, highly efficient serum concentration of lycopene can 
produce significant effects on participants who are obese. Thus, future research should 
test if serum lycopene has a dose-dependent manner on the incidence of metabolic syn-
drome among obese individuals. 
In addition, future research should also determine what the cut-off value of the ratio of 
serum concentration of lycopene to the amount of inflammation and/or oxidative stress in 
the body is for substantially reducing the prevalence of metabolic syndrome, separately 
for normal weight, overweight and obese individuals. This information on the effects of 
lycopene for individuals with different BMI statuses is expected to be very important for 
future dosage recommendations. 
Although serum triglyceride is strongly associated with inflammation and oxidative 




stress. Therefore, more direct measures of inflammation and/or oxidative stress, such as 
Interleukin (TNF-α, IL-8) and reactive oxygen species (ROS), are needed to estimate the 
health effects of lycopene based on the ratio of serum concentration of lycopene to the 
amount of inflammation and oxidative stress.  
For the health effect of serum lycopene on mortality among participants with metabolic 
syndrome, although our findings support the positive health effect of lycopene on mortality 
for individuals with metabolic syndrome, there are two issues that need to be solved in 
future research. One issue is the change of serum lycopene during the whole following-
up time. Due to the cross-sectional design of NHANES, we do not know if these partici-
pants have changed their serum concentration of lycopene during the following-up time. 
Therefore, a new prospective study for the health effect of lycopene on mortality should 
have periodic tests of serum concentration of lycopene. Another issue is what causes the 
reduced mortality among these individuals with a higher level of serum lycopene. In this 
study, we only know higher serum lycopene has an association with a lower mortality 
among individuals with metabolic syndrome. Future research can help us to understand 
what specific disease-related mortality could be reduced in individuals with a higher level 
of serum lycopene.   
For the additive health effect of physical activity and lycopene, serum lycopene is an 
objective variable; however, physical activity is a self-reported variable which is less ac-
curate among obese individuals than individuals who are normal weight and overweight. 
Therefore, inaccurate self-reported physical activity will lead to a misclassification error in 
current study. Therefore, in future research, more objective measurements of physical 
activity, such as an accelerometer measurement, should verify the additive effect of phys-




In addition, physical activity has complex mechanisms on the morbidity and mortality 
of metabolic syndrome, such as controlling weight, reducing serum concentration of tri-
glyceride, increasing high-density lipoprotein, improving insulin sensitivity, reducing blood 
pressure and decreasing inflammation reactions and inducting an anti-inflammatory envi-
ronment. Therefore, future research should estimate the possible additive effect of 
physical activity and lycopene on metabolic syndrome and mortality when all these varia-
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